^
BIOMARKER:

BAX expression

i
Other names: BAX, BCL2L4, BCL2-associated X protein
Entrez ID:
Related biomarkers:
5h
After miR-29c-3p-mimics+sh-CDCA4 was transfected into M21 and C8161 cells, the proliferation, invasion, and apoptosis were not different from those in the miR-NC group transfected with unrelated sequences. Overexpression of miR-29c-3p suppresses CDCA4 expression and decreases proliferation, migration, invasion, apoptosis, and EMT of MM cells, thus hindering MM progression.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • VIM (Vimentin)
|
BCL2 expression • CDH1 expression • BAX expression • VIM expression
1d
Compound BI9 showed remarkable inhibition of tubulin polymerization with the colchicine binding site of tubulin. In addition, compound BI9 promoted apoptosis by regulating the expression of pro-apoptotic protein BAX and anti-apoptotic proteins Bcl-2. These results provide guidance for further rational development of potent tubulin polymerization inhibitors for the treatment of cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BAX expression
|
colchicine
2d
Quer potentiates the sensitivity of breast cancer to 5-FU so that this combination may be proposed as a treatment for breast cancer. Therefore, this combination can be suggested for future in vivo studies.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP9 (Caspase 9)
|
BCL2 expression • TP53 expression • BAX expression
|
5-fluorouracil
3d
Itraconazole can inhibit proliferation of DLBCL cells in a concentration-and time-dependent manner. In addition, the combination of ASS and itraconazole show a synergistic effects, which may be related with the down-regulated protein expression of SMO and Glil of Hedgehog signaling pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • SMO (Smoothened Frizzled Class Receptor) • GLI1 (GLI Family Zinc Finger 1) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
|
itraconazole
3d
The results of this study show that PIC may be a promising therapeutic agent for the treatment of CRC. PIC might inhibit the proliferation of CRC cells and induce apoptosis via multiple mechanisms that involve its antioxidant effect and inhibition of NF-κβ and Ras/PI3K/Akt/mTOR signaling.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • PCNA (Proliferating cell nuclear antigen) • CAT (Catalase)
|
BAX expression
3d
These results indicated that TFLS could suppress PCa cell growth in vivo and inhibit PCa cell proliferation and metastasis in vitro through induction of apoptosis and phenotypic reversal of EMT, which may be achieved by inhibiting the AKT/mTOR and NF-κB signaling pathways. Taken together, our data provide new insights into the role of TFLS as a novel potent anti-cancer agent for the treatment of PCa.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • BAX (BCL2-associated X protein) • VIM (Vimentin)
|
BCL2 expression • CDH1 expression • BAX expression • VIM expression
3d
The present study indicated the therapeutic potential of gigantol in patients with NSCLC. In addition, DEK may serve as a novel therapeutic target to enhance the effects of gigantol treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
3d
The development of resistance against common chemotherapeutics such as 5-fluorouracil (5-FU) remains a big burden for CRC therapy... We demonstrated that melatonin exerts a reversing effect on the resistance to apoptosis by targeting oxidative stress, XIAP and survivin in CRC cells. Therefore, more studies need for better understanding of underlying mechanisms for beneficial effects of combination of melatonin and 5-FU.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BIRC5 (Baculoviral IAP repeat containing 5) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • XIAP (X-Linked Inhibitor Of Apoptosis) • CAT (Catalase)
|
BCL2 expression • BIRC5 expression • BAX expression
|
5-fluorouracil
3d
Compound 6 achieved the best cytotoxic activities on both HepG-2 and HuH-7 cell lines with IC values of 1.53 and 3.06 µM, respectively, and also it showed the most inhibitory activities on HDAC1, HDAC4, and HDAC6 with IC values of 1.76, 1.39, and 3.46 µM, respectively, compared to suberoylanilide hydroxamic acid (SAHA) as a reference drug (IC = 0.86, 0.97, and 0.93 µM, respectively)...In silico ADMET and toxicity studies revealed that most of the synthesized compounds have accepted profiles of drug-likeness with low toxicity. Finally, an interesting SAR analysis was concluded to help the future design of more potent HDACIs in the future by medicinal chemists.
Preclinical • Journal • IO biomarker • Epigenetic controller
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • HDAC1 (Histone Deacetylase 1)
|
BAX expression
|
Zolinza (vorinostat)
3d
For the first time, we determined the significance of EHMT2 in MCL and identified potential EHMT2-regulated genes.
Journal • Epigenetic controller
|
CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • HIP1 (Huntingtin Interacting Protein 1) • CASP3 (Caspase 3) • CD5 (CD5 Molecule) • HDAC1 (Histone Deacetylase 1) • HDAC2 (Histone deacetylase 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
CCND1 expression • BAX expression
3d
Moreover, systemic administration of COG-133-NPs loaded with MDB5 and SF2523 resulted in decreased tumor burden compared to non-targeted drug-loaded NPs, without any hepatic toxicity. In conclusion, our nanomedicine of MDB5 and SF2523 offers a novel therapeutic strategy to treat chemoresistant MB.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • BAX (BCL2-associated X protein) • BRD4 (Bromodomain Containing 4)
|
MYC amplification • CCND1 expression • BAX expression
|
COG 112 • COG 133 • SF2523
6d
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CCND1 (Cyclin D1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • PCNA (Proliferating cell nuclear antigen)
|
CCND1 expression • TP53 expression • BAX expression • PCNA expression
6d
Taken together, our findings support the idea that Gemini-Cur has the potential to be considered as an anticancer agent.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BIRC5 (Baculoviral IAP repeat containing 5) • BAX (BCL2-associated X protein)
|
BCL2 expression • BIRC5 expression • BAX expression
6d
Moreover, the down-regulation of JAK2-STAT3 signaling pathway was responsible for the underlying pro-apoptosis mechanism of panaxadiol, and this result was in good agreement with molecular docking analysis between panaxadiol and STAT3. In conclusion, our work comprehensively explored the anti-tumor ability in PANC-1 and Patu8988 cells of panaxadiol and provided a potential choice for the clinical treatment of pancreatic cancer patients.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BAX expression
7d
Our findings indicate that scoparone inhibits pancreatic cancer cell proliferation in vitro and in vivo, inhibits migration and invasion, and induces cycle arrest and apoptosis in vitro through the PI3K/Akt signaling pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen)
|
BAX expression
8d
No cytotoxic effects were observed in peripheral blood monocytes at the same concentrations. In addition, gene expression analysis by RT-PCR of apoptotic biomarkers (Bax, survivin, and Ki-67) allowed the study of the apoptotic mechanism induced by DcL-ASNase on THP-1 cells.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5) • BAX (BCL2-associated X protein)
|
BAX expression
10d
Docetaxel could inhibit the proliferation in ECA109 cell line. p21, bax, bcl-2 and other related proteins can regulate cell cycle phase distribution and induce cell apoptosis, thereby increasing the radiosensitivity effect of docetaxel in ECA109 cell line.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BAX expression
|
docetaxel
10d
In vitro, the protein and mRNA expressions of FAK, PI3K, AKT and mTOR in β-carboline alkaloids groups were significantly lower than those in control and fluorouracil groups (P<0.05)...Conclusively, β-carboline alkaloids can reduce FAK, PI3K, AKT and mTOR expressions at both protein and mRNA levels in SGC-7901 cells and tumor tissues formed by SGC-7901 cells. They may be targets of β-carboline in FAK/PI3K/AKT/mTOR pathway.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
|
5-fluorouracil
12d
In addition, the induction of DR5 by CSC-3436 was found to be dependent on the modulation of reactive oxygen species (ROS)/p38/C/EBP-homologous protein (CHOP) signaling pathways. Overall, our results indicated that CSC-3436 could potentiate the apoptotic effects of TRAIL through down-regulation of cell survival proteins and upregulation of DR5 via the ROS-mediated upregulation of CHOP protein.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • BIRC5 (Baculoviral IAP repeat containing 5) • BAX (BCL2-associated X protein) • XIAP (X-Linked Inhibitor Of Apoptosis) • TNFRSF10B (TNF Receptor Superfamily Member 10b)
|
BIRC5 expression • BAX expression
13d
In short, curcumin suppressed the proliferation and migration, blocked the cell cycle progression of AML cells, and sensitized AML cells to Adriamycin by regulating the HOTAIR/miR-20a-5p/WT1 axis. These findings suggest a potential role of curcumin and HOTAIR in AML treatment.
Journal
|
WT1 (WT1 Transcription Factor) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • HOTAIR (HOX Transcript Antisense RNA) • MIR20A (MicroRNA 20a)
|
BAX expression • HOTAIR overexpression • CDKN1B expression
|
doxorubicin hydrochloride
13d
In conclusion, findings from the present study suggested that circRNA_PTPRA may regulate HCC cell proliferation, invasion, apoptosis and migration by sponging miR-582-3p. This indicates that the circRNA_PTPRA/miR-582-3p axis may represent a potential target for HCC diagnosis and treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BAX (BCL2-associated X protein) • MMP9 (Matrix metallopeptidase 9)
|
BCL2 expression • CCND1 expression • BAX expression
13d
TNCu-A can effectively inhibit human umbilical vein endothelial cells (HUVECs) to form a tubular structure and it induces apoptosis of human triple-negative breast cancer MDA-MB-231 cells and HUVECs in vitro in a mitochondria dependent manner. Moreover, in vivo TNCu-A can remarkably inhibit the growth of triple-negative breast cancer from which MDA-MB-231 cells were xenografted into severely immunodeficient nude mice by inhibiting proliferation, inducing apoptosis of MDA-MB-231 cells by dramatically inhibiting the expression of the anti-apoptotic protein Bcl-2 and up-regulating the expressions of proapoptotic proteins caspase-9 and Bax, and simultaneously inhibiting tumor angiogenesis by decreasing the density of vascular endothelial cells and suppressing migration and even partially inducing apoptosis.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP9 (Caspase 9)
|
BCL2 expression • BAX expression
13d
Overall, the results suggested that an increase in cellular FA-SnO2 NPs internalization resulted in a significant induced cytotoxicity in SKOV3 cancer cells in dose-dependent mode through ROS-mediated cell apoptosis that may have occurred through mitochondrial pathway. Additionally, the results confirmed the safety of utilization FA-SnO2 NPs against living systems. So, FA-SnO2 NPs with a specific targeting moiety may be a promising therapeutic candidate for human ovarian cancer.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
TP53 expression • BAX expression
14d
lncRNA-ANRIL and SOX9 levels were higher in glioma patients than in healthy people. High-lncRNA-ANRIL and SOX9 levels were strongly associated with unfavorable prognosis of patients. The testing of biological behaviors revealed that lncRNA-ANRIL and SOX9 worked as tumor-promoting genes in glioma.
Clinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • BAX (BCL2-associated X protein) • SOX9 (SRY-Box Transcription Factor 9) • YBX1 (Y-Box Binding Protein 1)
|
BCL2 expression • BAX expression • SOX9 expression
14d
The aim of this study was to evaluate the potential of zoledronic acid (ZOL)-loaded lipidic nanoparticles (ZOL-NLCs) in enhancing the efficiency of paclitaxel (Pac) in the context of cytotoxicity, apoptosis, and invasiveness of HepG hepatocellular carcinoma cells. Besides, ZOL-incorporated lipidic nanoparticles reduced the migration of HepG cells significantly. Our data suggest that the formulation of ZOL into lipidic nanoparticles can be considered a potential therapeutic approach that can enhance the efficacy of Pac chemotherapy.
Journal
|
BCL2L1 (BCL2-like 1) • CDH1 (Cadherin 1) • BAX (BCL2-associated X protein)
|
CDH1 expression • BAX expression
|
paclitaxel • zoledronic acid
15d
LTX-315 can inhibit the resistance of OC cells to DDP in vitro and plays a role by regulating Beclin-1/phosphatidylinositol-3-kinase/mTOR signaling pathway.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • BECN1 (Beclin 1)
|
BCL2 expression • BAX expression
|
cisplatin • Oncopore (ruxotemitide)
15d
Cell Counting Kit-8 (CCK-8) was applied to detect the half maximal inhibitory concentration (IC) of cisplatin (DDP) on cell, and quantitative polymerase chain reaction (qPCR) was carried out to measure the relative expression level of miR-210...The expression of miR-210 has a correlation with chemoresistance of breast cancer MCF-7 cells. MiR-210 regulates the JAK-STAT signal transduction pathway by targeting PIAS4, thus exerting an effect on breast cancer chemosensitivity.
Journal • IO biomarker
|
BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MIR210 (MicroRNA 210) • PIAS4 (Protein Inhibitor Of Activated STAT 4) • STAT4 (Signal Transducer And Activator Of Transcription 4)
|
BCL2 expression • BAX expression
|
cisplatin
15d
TMEPAI was also shown to modify the effect of doxorubicin by reducing PI3K expressions and Akt phosphorylation in triple-negative breast cancer cells. Our findings indicate that TMEPAI promotes EMT and drug efflux transporters at least in part by shifting doxorubicin action from SMAD3 phosphorylation reduction to PI3K/AKT inhibition in triple-negative breast cancer cells.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • TGFB1 (Transforming Growth Factor Beta 1) • CASP9 (Caspase 9) • SMAD3 (SMAD Family Member 3)
|
BCL2 expression • BAX expression
|
doxorubicin hydrochloride
15d
PCSK9 might act as an oncogene or have an oncogenic role in the development and progression of colorectal cancer in vivo via activation of JAK2/STAT3/SOCS3 signaling.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • JAK2 (Janus kinase 2) • PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) • STAT3 (Signal Transducer And Activator Of Transcription 3) • BAX (BCL2-associated X protein)
|
BAX expression • PCSK9 expression • CSK overexpression
|
Repatha (evolocumab)
15d
We showed that high level expression of FBXL20 in cancer cells reduces therapeutic drug-induced apoptosis and promotes chemo-resistance. Overall, this study highlights the importance of targeting FBXL20 in cancers in conjunction with chemotherapy and may represent a promising anti-cancer strategy to overcome chemoresistance.
Journal • IO biomarker
|
FBXW7 (F-Box And WD Repeat Domain Containing 7) • BAX (BCL2-associated X protein) • FBXL20 (F-Box And Leucine Rich Repeat Protein 20)
|
BAX expression
16d
Antioxidants such as melatonin, N-acetylcysteine (NAC), α-tocopherol, and allopurinol alleviated TMT toxicity...The iron chelator deferoxamine ameliorated the alteration of apoptosis-related proteins through TMT exposure...Esculetin, meloxicam, celecoxib, and phenidone decreased TMT toxicity...The free calcium ion modulators nimodipine and BAPTA/AM contributed to neuronal survival against TMT toxicity. Inhibitors of the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin pathway, an autophagy regulator, decreased TMT toxicity. These results imply that TMT neurotoxicity is the chief participant in LOX- and COX-2-mediated apoptosis, partly via necrosis and autophagy in SH-SY5Y cells.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta) • CAT (Catalase)
|
BCL2 expression • BAX expression
|
Desferal (deferoxamine) • allopurinol • celecoxib oral • meloxicam • nimodipine
16d
In MCF-7 clones, these processes, as well as energetic metabolism, were remarkably suppressed. The data for the first time suggest that celecoxib induces apoptosis through upregulation of PRODH/POX in MCF-7 breast cancer cells.
Journal • PARP Biomarker
|
BAX (BCL2-associated X protein) • CASP9 (Caspase 9) • BECN1 (Beclin 1)
|
BAX expression
|
celecoxib oral
16d
Furthermore, the binding affinities and interactions of the n-hexane fraction's major metabolites were predicted against EGFR and BCL2 molecular targets using the molecular docking technique. These findings reveal the potential use of L. Sativum in the management of HCC.
Preclinical • Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • SMAD3 (SMAD Family Member 3)
|
EGFR expression • BCL2 expression • TP53 expression • BAX expression
16d
Our study revealed that melatonin could induce apoptosis by suppressing the PI3K/Akt/mTOR signaling pathway. Therefore, melatonin might serve as a potential therapeutic drug in the future treatment of gallbladder cancer.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BAX expression
16d
ARL inhibited 68% and 26% of Ehrlich ascites carcinoma cell growth in vivo in mice after treating with 3.0 and 1.5 mg/kg/day doses for five consecutive days. ARL increased the expression level of NFκB and arrested S cell cycle phase in EAC cells, in contrast, G/M phase was arrested by ARL and GDL in HCT-116.
Journal • PARP Biomarker
|
TP53 (Tumor protein P53) • BAX (BCL2-associated X protein) • FADD (Fas associated via death domain) • FAS (Fas cell surface death receptor) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
|
TP53 expression • BAX expression
17d
Preclinical • Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • CASP3 (Caspase 3)
|
TP53 mutation • BCL2 expression • MCL1 expression • BAX expression
19d
Apoptosis, as the mode of cell death, was also confirmed by the higher release of cytochrome C from mitochondria, the increased expression of caspase-3 and bax, along with down regulation of Bcl-2. These findings conclude that S. lappa is a cause of hepatic cancer cell death through apoptosis and a potential natural source suggesting furthermore investigation of its active compounds that are responsible for these observed activities.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BAX expression
20d
Low-temperature intervention at 16-18°C during the ischemia period showed optimal effects on the expressions of apoptotic factors during the development of PI with I/R-induced tissue damage.
Preclinical • Journal • IO biomarker
|
BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
BCL2 expression • BAX expression
20d
Moreover, the combination of carbon ion beam irradiation and miRNA-200c mimic increased the expression of apoptosis-related gene BAX, autophagy-related genes Beclin-1 and p62, addition of gemcitabine (GEM) further enhanced the expression of these genes. In vivo data showed that carbon-ion beam irradiation in combination with the miRNA-200c mimic effectively suppressed xenograft tumor growth and significantly induced tumor necrosis and cavitation. The combination of miRNA-200c mimic and carbon ion beam irradiation may be powerful radiotherapy that significantly kills pancreatic cancer cells containing CSCs and enhances the effect of carbon-ion beam irradiation compared to carbon-ion beam irradiation alone.
Preclinical • Journal
|
CD44 • BAX (BCL2-associated X protein) • MIR200C (MicroRNA 200c) • BECN1 (Beclin 1)
|
BAX expression
|
gemcitabine
20d
Knocking down its expression may inhibit myeloma proliferation, migration, and invasion by targeting and upregulating miR-635 and also promote cell apoptosis. As for multiple myeloma treatment, circ_0058063/miR-635 may provide new molecular targets.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
BCL2 expression • BAX expression
20d
Thus, the results indicate that lycorine efficiently enhances apoptosis and inhibits HT-3 cell proliferation. These outcomes collectively proposed that lycorine could be a beneficial chemotherapeutic agent for treating and managing human cervical carcinoma.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • JAK1 (Janus Kinase 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
BAX expression
20d
RNF144A-AS1/miR-665/HMGA1 axis implicated in the development of glioma.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • HMGA1 (High Mobility Group AT-Hook 1)
|
BCL2 expression • BAX expression
20d
PMTZ may suppress the proliferation and induce the apoptosis of CRC cells by inhibiting the PI3K/ AKT signaling pathway. This study reported, for the first time, the function of PMTZ in CRC cells and the underlying mechanism and further confirmed the potential antitumor effects of phenothiazine. The combination of bioinformatics analyses and experiments provides informative evidence for the reuse of drugs and the development of new drugs.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
BAX expression
|
promethazine
23d
The results showed that having anticancer compounds, ZEO can increase C3 and C9 and decrease Bcl-2 expressions, causing apoptosis in HT-29 cells in vitro. This can lead to the use of ZEO as a factor for colorectal cancer treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
BCL2 expression • BAX expression
23d
BZBS attenuates premature senescence possibly via the preservation of redox homeostasis and telomere integrity, and inhibition of apoptosis in rapid aging mouse. The mechanism governing the alterations may be associated with through the activation of Sirt6/NRF2/HO-1 and Sirt6/P53-PGC-1α-TERT signaling pathways. The results suggest that BZBS may provide a novel strategy for confronting aging and age-associated diseases.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TERT (Telomerase Reverse Transcriptase) • HMOX1 (Heme Oxygenase 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • SIRT6 (Sirtuin 6)
|
BCL2 expression • BAX expression • HMOX1 expression
24d
The results suggest that quercetin can alleviate the hormone, metabolic and ovulatory aberrations caused by PCOS, and provide experimental basis for the clinical application of quercetin in PCOS.
Preclinical • Journal • IO biomarker
|
AR (Androgen receptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • IL1B (Interleukin 1, beta)
|
BCL2 expression • AR expression • BAX expression • IL6 expression
|
metformin
24d
Cyclin D1 was involved in the anticancer effects of α-Mangostin on the cell cycle in MDA-MB-231 cells. α-Mangostin induces apoptosis, suppresses the migration and invasion of breast cancer cells through the PI3K/AKT signaling pathway by targeting RXRα, and cyclin D1 has involved in this process.
Journal • PARP Biomarker
|
CCND1 (Cyclin D1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BAX expression
24d
Western blot analysis further demonstrated that DLGAP5 knockdown downregulated the expression of CDK1, Cyclin B1 and Bcl-2, but upregulated Bax expression. Collectively, these data demonstrate that DLGAP5 might be a promising prognostic therapeutic target for OC treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
|
BCL2 expression • BAX expression
24d
In summary, the results from the present study indicated that C5orf66-AS1 knockdown inhibits OS cell proliferation and invasion via the upregulation of miR-149-5p. This findings may provide a promising novel target for the treatment of OS.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MMP9 (Matrix metallopeptidase 9) • MIR149 (MicroRNA 149)
|
BCL2 expression • BAX expression
27d
In conclusion, the study results suggest that OA induces apoptosis of A375SM and A375P cells in vitro and apoptosis of A375SM cells in vivo. Furthermore, the in vitro and in vivo anticancer effects were mediated by the NF-κB pathway.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
27d
Quantification by qRT-PCR showed increased expression levels of long non-coding RNAs RP11-838N2.4 and XIST in glioma cells treated with either bee venom or melittin. Overall, this study provides preliminary insight on molecular mechanisms via which bee venom and its main components can impact viability of glioma cells and warrants further investigation of its anticancer potential in gliomas.
Journal
|
BAX (BCL2-associated X protein) • BAK1 (BCL2 Antagonist/Killer 1) • XIST (X Inactive Specific Transcript)
|
BAX expression
|
Apitox (honeybee venom)
27d
When the maternal exercise was performed, the impairment of spatial learning memory in pups was ameliorated. Therefore, it can be seen that exercise during pregnancy of older and obese mothers is an important factor in fetal health management.
Preclinical • Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9) • NFKBIA (NFKB Inhibitor Alpha 2)
|
BCL2 expression • BAX expression
27d
Moreover, ADAM9 level showed a negative correlation with Bax and p62 expression within HCC tissues after radiotherapy. Taken together, ADAM9 decreased the radiosensitivity of HCC cells, and autophagy mediated this process.
Journal
|
NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • BAX (BCL2-associated X protein) • ADAM9 (ADAM Metallopeptidase Domain 9)
|
BAX expression
27d
Our study demonstrated that GNAZ plays a pivotal role as a potential oncogene and predicts poor prognosis in patients with HCC. It promotes tumor proliferation via cell cycle arrest, apoptosis, migration, and invasion. Thus, GNAZ may be a potential candidate biomarker providing useful insight into hepatocarcinogenesis and aggressiveness.
Journal
|
CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2)
|
BAX expression • CDK2 expression
27d
XPA overexpression was found to suppress HCC by inducing autophagy and apoptosis and repressing EMT and proliferation. Each of these effects may be involved in modulating the PI3K/Akt/mTOR signaling pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • VIM (Vimentin) • XPA (XPA, DNA Damage Recognition And Repair Factor) • BECN1 (Beclin 1)
|
BCL2 expression • BAX expression • VIM expression • XPA expression • XPA overexpression
29d
Finally, in vivo results showed that TSN suppressed OC xenograft tumor growth by inducing apoptosis and regulating the related protein expression levels of SKOV3 cells in transplanted tumors. Taken together, our data provide new insights into TSN as a potentially effective reagent against human OC through caspase-dependent mitochondrial apoptotic pathway.
Clinical • Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • BIRC5 (Baculoviral IAP repeat containing 5) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MMP2 (Matrix metallopeptidase 2) • CASP9 (Caspase 9) • MMP9 (Matrix metallopeptidase 9)
|
BCL2 expression • BIRC5 expression • BAX expression • PARP1 expression
29d
The regulation of FXT on cell viability, proliferation and apoptosis was reversed by miR-21-3p overexpression. FXT suppressed the development of glioma cells by downregulating miR-21-3p.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • BCL2L1 (BCL2-like 1) • MIR21 (MicroRNA 21) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CDK6 (Cyclin-dependent kinase 6) • MIR7 (MicroRNA 7)
|
BCL2 expression • CCND1 expression • BAX expression • miR-21 overexpression • CCNE1 expression • CDK6 expression
1m
We observed that all the three extracts showed the presence of bioactive compounds such as polyphenols or phytochemicals. The W. somnifera bioactive compounds were found to have the highest anti-proliferative activity on human liver cancer cells.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
1m
Our results indicate that maternal chewing could improve prenatal stress-related anxiety-like behavior and cognitive impairment in mouse offspring, at least in part by affecting hippocampal apoptotic response and central serotonin pathway.
Preclinical • Journal • IO biomarker
|
BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
1m
In this study, we found that that CDC20 was highly expressed in HCC and participated in radio resistance of HCC cells with P53 mutation Bcl-2/Bax via signaling pathway. This study is the first to present evidence that CDC20 may play a role in improving the efficacy of radiotherapy in HCC.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CDC20 (Cell Division Cycle 20)
|
TP53 mutation • BAX expression
1m
Tf-LP-ERN nanoparticles exhibited excellent anti-liver cancer activity in vivo and in vitro by inducing cellular apoptosis, exhibiting immunoregulatory actions, and targeting tumor tissues, and did so more effectively than free ERN and LP-ERN nanoparticles. These results suggest that the clinical utility of a Tf-conjugated LP ERN-delivery system for the treatment of liver cancer warrants exploration.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CCL11 (C-C Motif Chemokine Ligand 11) • IL10 (Interleukin 10) • CASP9 (Caspase 9) • SOD2 (Superoxide Dismutase 2)
|
BCL2 expression • BAX expression • PARP1 expression
1m
Furthermore, several studies have shown that the administration of these nanoparticles is safe due to their low toxicity in non-cancerous cells. In this review, the most relevant antecedents on the anticancer potential of selenium nanoparticles in prostate, breast, cervical, lung, liver, and colorectal cancer cell lines are discussed.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK2 (Cyclin-dependent kinase 2) • IRF1 (Interferon Regulatory Factor 1)
|
CCND1 expression • IRF1 expression • BAX expression • CDK2 expression
1m
In addition, davidone C can down-regulate the expression of p62, and simultaneously up-regulate the expression of LC3-I and LC3-II with a quantitative dependence, suggesting that the mechanism of apoptosis may be related to the autophagy signal pathway. All these results showed davidone C has potential effects on hepatocellular carcinoma.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP12 (Caspase 12 (Gene/Pseudogene)) • CASP7 (Caspase 7) • CASP9 (Caspase 9) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5)
|
BAX expression
1m
Furthermore, UF extract and UDCA treatment stimulated Akt phosphorylation and inhibited mTOR phosphorylation in these cells. These results indicate that UF extract and UDCA exert anticancer properties in FRO cells by inducing apoptosis and inhibiting angiogenesis via regulating the Akt/mTOR signaling pathway.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • TGFB1 (Transforming Growth Factor Beta 1) • SIRT1 (Sirtuin 1)
|
BCL2 expression • BAX expression
|
ursodeoxycholic acid
1m
The aim of this study was to investigate whether the stilbene derivatives piceid, resveratrol, and piceatannol have a radiosensitising effect on breast cancer cells (MCF-7)...This was due to a significant decrease in the activity of antioxidant enzymes, which resulted in the accumulation of formed reactive oxygen species (ROS). The effect of resveratrol and IR enhanced the expression of apoptotic genes, such as Bax, p53, and caspase 8, leading to apoptosis.
Journal
|
BAX (BCL2-associated X protein) • CASP8 (Caspase 8)
|
TP53 expression • BAX expression
|
piceatannol
1m
NU 9056 inhibited cell proliferation, arrested cell cycle in the G2/M phase, and induced apoptosis through the stimulation of ER stress, thus inhibiting the JAK2/STAT3 signalling pathway and regulating MAPK pathways in ENKTL cells.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BAX (BCL2-associated X protein) • CASP8 (Caspase 8) • XIAP (X-Linked Inhibitor Of Apoptosis)
|
BCL2 expression • MCL1 expression • BAX expression
1m
H inhalation following experimental SAH stabilized brain metabolites, improved recognition memory and reduced anxiety-like behavior, the neuronal apoptosis rate, phosphorylated p38 MAPK expression, cleaved caspase-3 expression and the Bax/Bcl-2 ratio. Collectively, the present results suggested that H inhalation can alleviate SAH-induced cognitive impairment, behavioral abnormalities and neuronal apoptosis in rats, possibly via inhibition of the p38 MAPK signal pathway.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
1m
In the present study, a magnetic niosomal nanocarrier for co-delivery of curcumin and letrozole into breast cancer cells has been designed...The findings of our research show the potential of designing magnetic niosomal formulations for simultaneous targeted delivery of both hydrophobic and hydrophilic drugs into cancer cells in order to enhance their synergic chemotherapeutic effects. These results could open new avenues into the future of nanomedicine and the development of theranostic agents.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MMP2 (Matrix metallopeptidase 2) • CASP9 (Caspase 9) • MMP9 (Matrix metallopeptidase 9)
|
BAX expression
|
letrozole
1m
Moreover, insufficient expression of Bax/Bak counteracted hypoxia-mediated downregulation of mitochondrial function, thereby adding to DHA-induced ROS production and lipid peroxidation in hypoxia. In summary, DHA-mediated cytotoxicity in normoxia depended on Bax/Bak expression, while cytotoxicity after treatment with DHA in hypoxia was regulated independently of Bax/Bak in HCT116 colorectal cancer cells.
Journal
|
BAX (BCL2-associated X protein) • BAK1 (BCL2 Antagonist/Killer 1)
|
BAX expression
1m
However, BV alone down-regulated P62 expression, LC3I/LC3II level, the number of cells arrested at S phase and the phosphorylation levels of AKT and mTOR, but upregulated the number of cells arrested at G0/G1 phase and Beclin1 expression, whereas AST-IV alone could reverse the effect of BV on autophagy-related proteins, the phosphorylation levels of AKT and mTOR. This paper demonstrates that AST-IV enhances the effect of BV on inhibiting proliferation and promoting apoptosis of lung adenocarcinoma cells through inhibiting autophagy pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • BECN1 (Beclin 1)
|
BCL2 expression • BAX expression
|
Avastin (bevacizumab)
1m
Results Osthole significantly inhibited the proliferation and induced the apoptosis of Tca8113 cells in a concentration-dependent manner,and it reduced the cell colony formation.Western blot results showed that osthole could up-regulate the expression of Bax and cleaved caspase-3 and down-regulate that of Bcl-2.At the same time,it increased the expression of LC3Ⅱ and P62 and reduced that of LC3Ⅰ. Conclusion Osthole may inhibit the proliferation of Tca8113 cells by promoting cell apoptosis and blocking autophagy flow to inhibit autophagy.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
1m
Our findings demonstrated that XQ-1H treatment could provide a neuroprotective effect against ischemic stroke induced by cerebral ischemia/reperfusion injury in vivo and in vitro through regulating neuronal survival and inhibiting apoptosis. The findings of the study confirmed that XQ-1H could be develop as a potential drug for treatment of cerebral ischemic stroke.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
|
quercetin (LY294002)
1m
TRPA1 mediates cisplatin-induced apoptosis in renal tubular cells via the calcineurin-nuclear factor of activated T-cells-p53 signaling pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • NFATC1 (Nuclear Factor Of Activated T Cells 1)
|
BCL2 expression • TP53 expression • BAX expression
|
cisplatin
1m
Our findings suggest that carvacrol suppresses proliferation, migration, invasion and promotes apoptosis in osteosarcoma cells, in part by regulating the Wnt/β-catenin signaling pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • MMP9 (Matrix metallopeptidase 9)
|
BCL2 expression • BAX expression
1m
The processes mainly involved the expression of caspases -3, -8, -9, AKT, p27, p53, BAX, and BCL2. The quoted results could lead to the classification of mushrooms as nutraceuticals used to prevent a variety of disorders or to support treatment of cancer diseases.
Review • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP9 (Caspase 9)
|
TP53 expression • BAX expression • CDKN1B expression
1m
Finally, ivermectin at low doses (2.5 and 5 µM) induced CRC cell arrest. Overall, ivermectin suppressed cell proliferation by promoting ROS-mediated mitochondrial apoptosis pathway and inducing S phase arrest in CRC cells, suggesting that ivermectin might be a new potential anticancer drug therapy for human colorectal cancer and other cancers.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP7 (Caspase 7)
|
BAX expression
|
ivermectin topical
1m
We suggest cypermethrin induces Sertoli cell apoptosis involving mitochondrial pathway associated with Ca regulated by Bcl-2 family and Ca/CaM/CaMKII pathway. The study provides a new insight into mechanisms involved in cypermethrin-induced male reproductive toxicology.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
1m
<b></b> This study gives deep insight into evaluating natural extracts and/or bioactive ingredients derived from the <i>C. spicatus</i> plant and eventually exhibited a promising apoptosis-inducing anti-cancer agent.
Preclinical • Journal
|
BAX (BCL2-associated X protein)
|
BAX expression
1m
Molecular docking provides assertive evidence for the interaction between Que ligand and PTEN receptor. Consequently, these results indicate that Que effectively antagonizes IMI-induced mitochondrial apoptosis in grass carp hepatocytes via regulating the PTEN/PI3K/AKT pathway.
Journal • IO biomarker
|
PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
1m
Moreover, LC3-II production as well as autophagosomes formation was observed as demonstrated by western blot and immunofluorescence, indicating elevated autophagy network by Sendeng-4 stimulation. Collectively, we concluded that Sendeng-4 might be used as an anticancer drug for melanoma.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
1m
Moreover, the CBS knockdown weakened the cancer cell-inhibiting effectiveness of DRE. Therefore, DRE may affect ESCC progression through the regulation of PI3K/Akt and Ras/Raf/ERK signal pathways as well as the endogenous CBS/HS system, and consequently, serve as an effective anti-cancer alternative for human ESCC treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression • BAX expression
1m
In conclusion, Ampelopsin-induced mitochondria damage leads to loss of mitochondria membrane potential, overproduction of ROS and activation of Bax, increasing mitochondria membrane permeability and ultimately inducing breast cell apoptosis. These findings provided a new perspective on the role of Ampelopsin in breast cancer prevention and treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
1m
In conclusion, ethyl acetate extract from B. bipinnata has a significant protective effect on the damage of L02 cells caused by endoplasmic reticulum stress. The mechanism may be related to the inhibition of endoplasmic reticulum stress and the down-regulation of apoptosis in cells through the PERK/eIF2α/ATF4/CHOP signaling pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • ATF4 (Activating Transcription Factor 4) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5)
|
BAX expression
1m
The AKT-1/p-Akt-1 and AMPK/p-AMPK ratio increased in treated cells (P  .05). Our results indicated that the combination of Sulindac and VD has a growth-inhibiting effect on MCF-7 cells through AMPK/Akt/β-catenin axis.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • BAX (BCL2-associated X protein) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • RELA (RELA Proto-Oncogene)
|
BCL2 expression • BAX expression
|
sulindac
1m
Compound 17 exhibited the best IC being equipotent with the positive control doxorubicin (IC 0.06 μM) and better than 5-fluorouracil (IC 2.13 μM). Additionally, in vivo testing in a mouse model of breast cancer affirmed the anti-tumor efficacy of 17. Finally, docking of 17 against EGFR ATP binding site demonstrated its ability to bind with EGFR resembling erlotinib.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CASP8 (Caspase 8) • CASP9 (Caspase 9)
|
TP53 expression • BAX expression
|
erlotinib • 5-fluorouracil • doxorubicin hydrochloride
1m
Molecular docking confirmed that 16 could bind to the active sites of Bcl-2, p65, and p38 reasonably. The above results suggested that 16 has enormous potential to be developed as a multifunctional agent for the clinical treatment of liver cancers and inflammatory diseases.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
1m
Additionally, the findings of this study also showed Tilianin inhibited JAK2/STAT3 signaling (downregulated expression of pJAK2, JAK2, pSTAT3, and STAT3) with no change in mRNA expression level of ERK indicating its non-involvement in the apoptotic and/or growth inhibition of ovarian cancer cells. In conclusion, the findings of this exploration provided clear evidence of anti-cancer effects of Tilianin in PA-1 cells through its anti-proliferative action, ability to induce apoptosis both through extrinsic and intrinsic pathways, cell cycle (G1/S) arrest and JAK2/STAT3 signaling inhibition.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BAX (BCL2-associated X protein) • CASP8 (Caspase 8) • CASP9 (Caspase 9)
|
BCL2 expression • CCND1 expression • BAX expression
1m
Preclinical • Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CASP9 (Caspase 9)
|
TP53 expression • BAX expression
1m
Expectedly ICC results confirmed the up-regulation of P53 proteins in treated samples. Our results indicate the cytotoxicity of hypericin on Huh7 cells by affecting the expression of the gate keeper gene P53; furthermore it is suggested that this herb can be utilized simultaneously with modalities targeting P53 up-regulation or related molecular pathways.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • TP53 expression • BAX expression
2ms
yoga training combined with low and high doses of VD improved physical fitness and psychological measures while only in combination with a high dose of VD positively modified the leukocytes cell survival-related gene expression.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • BAX (BCL2-associated X protein)
|
BCL2 expression • TP53 expression • BAX expression
2ms
Similarly, Hoechst staining indicates a remarkable increase in cells with apoptotic morphology after treating with AuNPs. Overall, our findings show that AuNPs significantly provoke ROS production, induce apoptosis, and suppress cell migration in bladder cancer 5637 cells.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP7 (Caspase 7)
|
BCL2 expression • BAX expression • BAX overexpression
2ms
Furthermore, miR-216 is an underlying target of isoflurane. Thus, isoflurane could be adopted for CRC treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MIR216A (MicroRNA 216a)
|
BCL2 expression • BAX expression
|
isoflurane
2ms
The colony number decrease in cells was 50.54%, 37.88% and 27.12% following exposure to compounds 2d, 2g and 4b respectively at 10 μM. We also show that treating the neuroblastoma cell line with these compounds resulted in a significant alteration in caspase-3 and PARP-1 cleavage.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression • PARP1 expression
2ms
The effects of Rh2 were suggested to occur through the inhibition of total HDAC activity, which subsequently induced MAPK signaling and down-regulated the expression of HIF.
Journal • IO biomarker • Epigenetic controller
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • CD31 (Platelet and endothelial cell adhesion molecule 1) • HDAC1 (Histone Deacetylase 1) • HDAC2 (Histone deacetylase 2) • IL10 (Interleukin 10)
|
BCL2 expression • KIT expression • CCND1 expression • BAX expression • CD31 expression • IL6 expression
2ms
Docking analysis showed that 4k could reasonably bind to the active sites of Bcl-2, NF-κB/p65, PI3K and AKT. This result suggested that 4k could be used as a new type of NF-κB inhibitor, which provides a scientific basis for further research into the treatment of hepatoma.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IFNG (Interferon, gamma) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • RELA (RELA Proto-Oncogene)
|
BCL2 expression • BAX expression
2ms
A significant correlation was observed: patients with SOX2 overexpression had a lower 5-year overall survival rate (p = 0.04); however, there was no significant association between Bcl-2 and survival (p = 0.5). Collectively, overexpression of SOX2 and Bcl-2, alone or combined, may be a potential marker to evaluate prognosis and response to HCC treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • SOX2
|
BCL2 overexpression • BCL2 expression • BAX expression • SOX2 overexpression
2ms
However, overexpression of ADAM15 had the opposite results. Collectively, our findings demonstrated that ADAM15 was connected with poor prognosis of HCC patients, and could be considered as a potential biomarker for the diagnosis and treatment of HCC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • BAX (BCL2-associated X protein) • VIM (Vimentin) • TJP1 (Tight Junction Protein 1)
|
BCL2 expression • CDH1 expression • BAX expression • VIM expression
2ms
These results suggest that ACP can alleviate the progression of liver cancer through the mechanisms predicted by network pharmacology, and provide a basis for the further understanding of the application of ACP in anti-cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9)
|
BCL2 expression • BAX expression
2ms
By targeting MM and bone cells simultaneously, combination RaST suppressed MM disease progression through a multi-prong action on the vicious cycle of bone cancer. Instead of using the standard multidrug approach, our work reveals a unique photophysical treatment paradigm that uses nontoxic doses of a single light-sensitive drug directed orthogonally to cancer and bone cells, followed by radionuclide-stimulated generation of ROS to inhibit tumor progression and minimize osteolysis in both immunocompetent murine and immunocompromised human MM models.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • ITGA4 (Integrin, alpha 4) • ITGB1 (Integrin Subunit Beta 1)
|
BCL2 expression • TP53 expression • BAX expression
2ms
In vivo experiments further verified the results obtained from in vitro experiments. Silent FOSL1 strengthened the radiosensitivity of glioma by down-regulating miR-27a-5p.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • MIR27A (MicroRNA 27a)
|
BCL2 expression • BAX expression
2ms
These effects found to be mediated via interrupting ERK1/2-HIF-1α-p300/CREB interactions. Therefore, our findings revealed that disrupting ERK1/2-HIF-1α-p300/CREB interplay might create a novel therapeutic target for the management of HCC.
Preclinical • Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • KDR (Kinase insert domain receptor) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CD34 (CD34 molecule) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9)
|
KDR expression • TP53 expression • BAX expression
|
albendazole
2ms
Renal IRI-induced liver damage in rats was alleviated by colchicine through its anti-inflammatory, anti-apoptotic, and anti-fibrotic actions.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TNFA (Tumor Necrosis Factor-Alpha) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • BAX (BCL2-associated X protein) • TGFB1 (Transforming Growth Factor Beta 1) • TLR4 (Toll Like Receptor 4)
|
BCL2 expression • BAX expression
|
colchicine
2ms
Combined high-energy ECSW and 5-FU offers an additional benefit for suppressing the cancer cell proliferation and tumor growth.
Journal • PARP Biomarker
|
BRAF (B-raf proto-oncogene) • KRAS (KRAS proto-oncogene GTPase) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • CASP3 (Caspase 3) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4)
|
BAX expression
|
5-fluorouracil
2ms
In conclusion, MF provided protective mechanisms against the DEHP-mediated deterioration of testicular functions partially through its antioxidant, anti-inflammatory, and anti-apoptotic properties. It also involved the restoration of steroidogenesis and spermatogenesis through the modulation of Nrf2/HO-1, NF-κB/Cyt c/HSP70, and c-Kit signaling cascades.
Preclinical • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • FASLG (Fas ligand)
|
BAX expression
2ms
TUNEL assay showed rAd-p53 + PTX induced notable apoptosis in tumor tissues. rAd-p53 showed good sensitization of PTX in vitro and in vivo through inducing DNA damage induced-apoptosis indicated p53-dependent apoptosis was essential for the antitumor effect of PTX in PTC.
Journal • PARP Biomarker
|
CCND1 (Cyclin D1) • BCL2L1 (BCL2-like 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BAX expression
|
paclitaxel
2ms
Puerarin has the anti-Alzheimer's disease (AD) activity,which can reverse nerve injury induced by Aβand inhibit neuronal apoptosis.However,its potential pharmacodynamic mechanism still needs to be further researched.The occurrence and development of AD is due to the change of multiple metabolic links in the body,which leads to the destruction of balance.Puerarin may act on multiple targets and multiple metabolic processes to achieve therapeutic purposes.Quantitative proteomic analysis provides a new choice to understand the mechanism as completely as possible.This research adopted SH-SY5Y cells induced by Aβ_(1-42)to establish AD cell model,and Aβimmunofluorescence detection showed that Aβdecreased significantly after puerarin intervention.The mechanism of puerarin reversing SH-SY5Y cell injured by Aβ_(1-42)was further explored by using label-free non-labeled quantitative technology and Western blot detection based on bioinformatics analysis result.The results showed that most of the differential proteins were related to biological processes such as cellular component organization or biogenesis,cellular component organization and cellular component biogenesis,and they mainly participated in the top ten pathways of P value such as pathogenic Escherichia coli infection,m TOR signaling pathway,regulation of autophagy,regulation of actin cytoskeleton,spliceosome,hepatocellular carcinoma,tight junction,non-small cell lung cancer,apoptosis and gap junction.Annexin V/PI flow cytometry and TUNEL were used to detect apoptosis,and the results showed that Aβdecreased significantly and the rate of apoptosis decreased significantly after puerarin intervention.Western blot analysis found that the protein expression level of autophagy related protein LC3Ⅱwas up-regulated after Aβinduction,and the degree of this up-regulation was further enhanced in puerarin intervention group.The trend of the ratio of LC3Ⅱ/LC3Ⅰamong groups was the same as the protein expression level of LC3Ⅱ,the protein expression level of p62 in the control group,AD model group and puerarin intervention group decreased successively.Protein interaction network analysis showed that CAP1 was correlated with TUBA1B,HSP90AB2P,DNM1L,TUBA1A and ERK1/2,and the correlation between CAP1 and ERK1/2 was the highest among them.Western blot showed that the expressions of p-ERK1/2,Bax and CAP1 were significantly down-regulated and the protein expression level of Bcl-2 was significantly up-regulated after puerarin intervention.Therefore,puerarin might improve the SH-SY5Y cells injured by Aβ_(1-42)through the interaction of multiple biological processes and pathways in cells multiple locations,and CAP1 might play an important role among them.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression • BAX expression
2ms
However, MVD of APR-TACE2 was lower than that of groups TACE, IVR-TACE with significant statistical difference (p < 0.05). Arterial instillation of rapamycin+TACE in treatment of rabbit hepatic xenograft tumors can reduce tumor neovascularization and inhibit iNOS, HIF-1α, VEGF, Bcl-2, and Bax protein expression.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression • HIF1A expression
|
sirolimus
2ms
Aspirin eugenol ester (AEE) is a new pharmaceutical compound esterified by aspirin and eugenol, which has anti-inflammatory, antioxidant, and other pharmacological activities. PI3K inhibitor LY294002 and the silencing of PI3K by shRNA could weaken the protective effect of AEE on PQ-induced SH-SY5Y cells. Therefore, AEE has a protective effect on PQ-induced SH-SY5Y cells by regulating the PI3K/Akt signal pathway to inhibit oxidative stress.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CAT (Catalase)
|
BCL2 expression • BAX expression
|
quercetin (LY294002) • aspirin
2ms
05). The above results indicate that SL extract can provide protective effect on ECV304 cells injury induced by TNF-α,alleviate oxidative stress injury,inflammation and apoptosis,and its mechanism may be related to regulating Nrf2/Keap1 signaling pathway.
Journal • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • HMOX1 (Heme Oxygenase 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • NQO1 (NAD(P)H dehydrogenase, quinone 1) • CASP9 (Caspase 9) • IL1B (Interleukin 1, beta)
|
BCL2 expression • BAX expression
2ms
To summarize, the findings clearly demonstrate that Se-rich RJ could inhibit tumor growth by inducing apoptosis and inhibiting angiogenesis as well as exhibit anti-tumor effects by improving immune function and antioxidant activities. The results indicated that Se-rich RJ could be a potential functional food for the management and prevention of cancer.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CASP9 (Caspase 9)
|
BCL2 expression • BAX expression • PTGS2 expression
2ms
MiR-142-3p can inhibit the proliferation of Nalm6 cells by targeting down-regulation the expression of HOXA5, arrest the G phase of cells, and promote apoptosis of the cells.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CASP3 (Caspase 3) • MIR142 (MicroRNA 142)
|
BCL2 expression • CCND1 expression • BAX expression
2ms
We further confirmed that downregulated expression of KIF11 promoted cell apoptosis and significantly increased Bcl-2 and Bax expression. Our findings demonstrate that KIF11 plays a role in promoting the development of human WT and can serve as a potential molecular marker for the treatment of WT.
Clinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • KIF11 (Kinesin Family Member 11)
|
BCL2 expression • BAX expression
2ms
The combination of bufalin and hydroxycampothecin also increased the expression of apoptosis-related proteins Bax, p53, PDCD4 and GSK-3β, and decreased the expression of Bcl-XL and p-AKT compared with a single drug treatment. The present study suggested that the combination of bufalin and hydroxycampothecin improved the inhibitory effects of both drugs on CRPC tumors in vivo, potentially via the regulation of the PI3K/AKT/GSK-3β and p53-dependent apoptosis signaling pathways.
Preclinical • Journal
|
BCL2L1 (BCL2-like 1) • BAX (BCL2-associated X protein) • PCNA (Proliferating cell nuclear antigen)
|
TP53 expression • BAX expression • PCNA expression
2ms
Fluorouracil (5-FU) and 0 nmol/L toosendanin (TSN) were used as positive control and negative control, respectively...In addition, the mRNA and protein expression levels of Bax, Cyt c and APAF-1 were increased significantly (P<0.05), while the mRNA and protein expression levels of Bcl-2 were decreased significantly (P<0.05). Toosendanin up-regulates the expressions of Bax, Cyt c and APAF-1, down-regulates the expression of Bcl-2 gene, enhances the activities of caspase-3 and caspase-9, and induces the apoptosis of human gastric cancer MGC-803 cells.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • APAF1 (Apoptotic peptidase activating factor 1)
|
BCL2 expression • BAX expression
|
5-fluorouracil
2ms
Compared with the blank control group, the relative expression levels of G6PD and bcl-2 protein in miR-335-5p mimic group were decreased significantly, and the expression levels of Bax and caspase-3 protein were increased significantly (P<0.05). MiR-335-5p may inhibit the proliferation and promote apoptosis of colon cancer cells by targeting G6PD.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MIR335 (MicroRNA 335)
|
BCL2 expression • BAX expression
2ms
Mitocans, in particular the combined drug, 3Br-P + DCA, could be regarded and more evaluated as a safe and effective compound for CRC treatment. Targeting hexokinase and pyruvate dehydrogenase kinase enzymes may be an option to overcome 5-FU -mediated chemo-resistant in colorectal cancer.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • HK1 (Hexokinase 1)
|
BCL2 expression • BAX expression
|
5-fluorouracil • dichloroacetate
2ms
RESULTS Our results showed that, compared with male mice, female mice showed more serious damage: reduced glycogen and higher degree of necrosis, and the levels of heatshock protein 27 (HSP27), heat-shock protein 70 (HSP70), proliferating cell nuclear antigen (PCNA) and B cell lymphoma/lewkmia-2 (Bcl-2) were significantly lower than in the male group (P<0.05 or P<0.01), while the results of Bcl-2-associated X protein (Bax), cysteinyl aspartate specific proteinase 3 (Caspase3), and cytochrome P450 2E1 (CYP2E1) were the opposite (P<0.05 or P<0.01). CONCLUSIONS The findings from this study showed that, compared with male mice, at 24 h after CCl₄ toxicity, female mice showed more severe changes of hepatocyte necrosis and PAS-positivity, with significantly reduced expression of HSP27, HSP70, PCNA, and Bcl-2, and significantly increased expression of Bax, caspase-3, and CYP2E1.
Preclinical • Journal • IO biomarker
|
BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • HSPB1 (Heat shock 27kDa protein 1) • PCNA (Proliferating cell nuclear antigen)
|
BCL2 expression • BAX expression • HSPB1 expression • PCNA expression
2ms
In vivo experiment, STAT3 inhibitor further suppressed the size of NSCLC tissues, and further down-regulated the expression of ROR1 and ABCB1 while up-regulated the expression of p53 in NSCLC tissues. In conclusion, STAT3 inhibitor enhanced the antitumor effect of gefitinib on EGFR-mutated NSCLC cells through regulating ROR1/ABCB1/P53 pathway.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • CASP3 (Caspase 3) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
TP53 mutation • EGFR mutation • EGFR expression • BCL2 expression • ROR1 expression • TP53 expression • BAX expression • STAT3 expression
|
gefitinib • napabucasin (BBI608)
2ms
Pegvisomant (PEG), an antagonist of GH receptor, was initially developed to treat patients with acromegaly, but it has shown potential to treat some tumors...Conclusion In conclusion, IGF1 antagonism is leading modulator in A549 lung cancer cells and autocrine/paracrine signaling in the GH/IGF1 axis is evidenced for adenocarcinoma cells, with changes in expression of GH and GH-receptor, which may imply that therapeutics need to be based on time changing kinase inhibitors and possible biomarkers to proper adjustments. Acknowledgements: the authors thank to I. Mendieta, J.E. Soto, J. Escobar, A.L. Gutiérrez for design and technical assistance; This work has been funded by Consejo Nacional de Ciencia y Tecnología (CONACYT) and UAQ-FCQ201820
IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IGF1 (Insulin-like growth factor 1) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
|
Somavert (pegvisomant)
2ms
In conclusion, BmKn-2 inhibited proliferation and induced apoptosis in both CHMp-5b and CHMp-13a cell lines via down-regulation of Bcl-2 and up-regulation of Bax relative mRNA expression. Therefore, BmKn-2 could be feasible as candidate treatment for CMGTs.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
2ms
These findings indicate that USP9X high expression plays a significant part in cisplatin-resistance of NPC. This study elucidated the possible mechanism of cisplatin resistance in NPC cells and may have implications for the therapeutic reversal of cisplatin resistance.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • BAX (BCL2-associated X protein) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
BCL2 expression • BAX expression
|
cisplatin
2ms
The use of Smokeless tobacco products can lead to major cellular and surface changes in the gingiva and its appearance. The consequences of these changes are not limited to oral cancer but also increases a person's risk for dental and periodontal disease.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
2ms
Lastly, we confirmed that TBB effectively eliminated tumor growth without causing overt toxicity to healthy tissues in the xenograft tumor model. The exploration of anticancer activity and the underlying mechanism of TBB suggested its usage as a promising chemotherapeutic agent for HCC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • BAX (BCL2-associated X protein) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen) • CCNB1 (Cyclin B1) • PGK1 (Phosphoglycerate Kinase 1)
|
BAX expression • PCNA expression
2ms
Along with strong antifungal activity against Talaromyces verruculosus, AKL showed antibacterial activity against Staphylococcus aureus, Shigella sonnei, and Bacillus cereus whereas the growth of Escherichia coli was not affected by the lectin. This study explores the antiproliferative and antimicrobial potentials of AKL as well as its involvement in embryo defense of sea hare.
Journal
|
BCL2L1 (BCL2-like 1)
|
TP53 expression • BAX expression
2ms
In conclusion, our findings indicated that RHPN1-AS1 plays an important role in NPC via activating mTORC1 signaling which is modulated by CELF2. RHPN1-AS1 may serve as a potential therapeutic target for NPC treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CELF2 (CUGBP Elav-Like Family Member 2) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
BCL2 expression • BAX expression
2ms
In general, our study suggested that the hWJSC-CM and hWJSC-CL inhibits proliferation and viability of GC cell line AGS through induction of apoptosis, as well as modification of NF-κB and MAPK signaling pathways.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BAX expression
2ms
KRG induced apoptosis via extrinsic and intrinsic pathway in MCF-7 breast cancer cells and MCF-10A non-malignant cells. KRG may be safely used with regard to breast cancer risk in postmenopausal women to reduce the vasomotor symptoms.
Journal • IO biomarker
|
ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • FASLG (Fas ligand)
|
BCL2 expression • BAX expression
2ms
All these effects were reversed following transfection with miR-654-3p inhibitor. Taken together, the results of the present study suggest that circRNA_0000285 plays a vital role in thyroid cancer progression by regulating miR-654-3p, which provides a potential therapeutic target for this disease.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
2ms
What is more, in NSCLC cells, miR-195-5p was a target of MCM3AP-AS1, and the latter worked as a molecular sponge for miR-195-5p to regulate E2F3 expression. Collectively, MCM3AP-AS1, serving as a competitive endogenous RNA (ceRNA) to regulate miR-195-5p/E2F3 axis, promotes NSCLC progression, which is a promising therapeutic target for NSCLC.
Journal • IO biomarker
|
CDH1 (Cadherin 1) • BAX (BCL2-associated X protein) • TCF3 (Transcription Factor 3) • E2F3 (E2F transcription factor 3) • MIR195 (MicroRNA 195)
|
BCL2 expression • CDH1 expression • BAX expression
2ms
Baicalein inhibited cell viability and EMT, and induced cell apoptosis of Hela cells, through upregulating miR-183 via inactivation of the JAK2/STAT3 signaling pathway.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • CASP3 (Caspase 3) • VIM (Vimentin)
|
BCL2 expression • BAX expression
2ms
ZQD treatment led to increased caspase-3 and Bax expression. ZQD treatment could promote apoptosis of prostate cancer cells by promoting miR-143 upregulation, which could be a possible mechanism underlying the inhibitory effect of ZQD in prostate cancer in patient.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
2ms
Finally, upregulation of caspase-9, p53, and NO, with downregulation of TNF-α, NF-κβ, and inflammatory mediators of the PC-3 cells established the superiority of the micellar approach against prostate cancer. In summary, the acquired results highlighted the potentiality of the 2 ME-micellar delivery tool for controlling the growth of prostate cancer cells for improved efficacy.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • CASP9 (Caspase 9)
|
BCL2 expression • BAX expression
|
Panzem (2-methoxyestradiol)
3ms
Overall, GLA can protect AML-12 cells from lipid metabolism disorder caused by PA via balancing autophagy and apoptosis mediated by the LKB1-AMPK-mTOR pathway. Consequently, GLA, as a dietary supplement, can help to prevent and treat NAFLD by regulating lipid metabolism and autophagy.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • STK11 (Serine/threonine kinase 11) • BAX (BCL2-associated X protein) • ATG5 (Autophagy Related 5) • BECN1 (Beclin 1) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
|
BCL2 expression • BAX expression
3ms
Additionally, shikonin decreased the migration of SNU-C5RR cells via the upregulation of E-cadherin and downregulation of N-cadherin. Taken together, these results suggest that shikonin induces mitochondria-mediated apoptosis and attenuates epithelial-mesenchymal transition in SNU-C5RR cells.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
3ms
[Cu(phen)(L-tyr)Cl].3H20 holds great potential to be developed for breast cancer treatment.
Journal
|
CASP3 (Caspase 3) • CASP7 (Caspase 7) • CASP9 (Caspase 9)
|
TP53 expression • BAX expression
|
hydroxychloroquine
3ms
Consequently, our findings point to an important role of these three miRNAs in prostate cancer and indicate that miR-125b-5p, miR-145-5p and miR-221-3p are potential therapeutic targets against prostate cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • MIR221 (MicroRNA 221)
|
BAX expression
3ms
Our results revealed that MNNG was easier to induce malignant transformation of Het-1A cells transfected with HPV18. It is good evidence for the close relationship between HPV and the etiology of EC, providing foundation for further study in molecular mechanism and specific intervention targets.
Preclinical • Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BCL2 expression • MYC expression • BAX expression • BCL2/BAX ratio elevation
3ms
These observations showed that taurine inhibits HepG2 cell proliferation and restores the expression of miR-122-5p which inhibits the hallmark glycolytic enzymes and ultimately the metabolic activity of HCC cells. Tau is assumed to be a promising and effective antitumor therapy of HCC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • ALDOA (Aldolase Fructose-Bisphosphate A)
|
TP53 expression • BAX expression
3ms
EAAs and NEAAs addition in EY-free PVA extender improved sperm motility, with limited effect on acrosome integrity and gene expression of SMCP, BCL2 and BAX during dog sperm cryopreservation.
Journal • IO biomarker
|
BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
3ms
This is the first report to explain the intracellular pathway by which flavonoids and phenolic compounds-rich extracts of Vespa orientalis larvae could induce MCF7 cell viability loss through the initiation of apoptosis, activation of antioxidants, and inhibition of migration and inflammation. Therefore, these extracts could be used as adjuvants for anticancer drugs and as antioxidant and anti-inflammatory agents.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9)
|
BCL2 expression • BAX expression
3ms
Therefore, Rev may confer potential properties as a therapeutic anti-cancer agent. Additionally, TTK may serve as a molecular target for the treatment of gastric cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • MMP2 (Matrix metallopeptidase 2) • CASP9 (Caspase 9) • MMP9 (Matrix metallopeptidase 9)
|
BCL2 expression • BAX expression
3ms
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BAX expression
3ms
An in vivo tumor growth assay showed that MSX2 overexpression slowed the growth rate of osteosarcoma xenograft tumors. Thus, MSX2 loss plays a crucial role in the osteosarcoma phenotype by elevating SOX2 and TNF-α levels.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • SOX2 • MMP2 (Matrix metallopeptidase 2)
|
BAX expression
3ms
PLAC8 expression is closely related to neck metastasis and the prognosis of NPC. PLAC8 gene knockout significantly increases the radio-sensitivity of NPC cells in vivo by promoting apoptosis, which is an effective strategy for the radiotherapy sensitization of NPC.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PLAC8 (Placenta Associated 8)
|
BCL2 expression • BAX expression
3ms
Compared with the esophageal cancer patients treated with chemotherapy after TLS, the serum CA153, CA199, and CEA levels were significantly improved in the patients treated with radiotherapy. The Bcl-2 and Bax levels in the PBMCs tended close to normal. Therefore, undergoing radiotherapy after TLS is markedly effective in prolonging patients' survival times and improving their prognoses.
Clinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • CEACAM5 (CEA Cell Adhesion Molecule 5) • BAX (BCL2-associated X protein) • CD4 (CD4 Molecule) • Cancer antigen 19-9
|
BCL2 expression • BAX expression
|
cisplatin • 5-fluorouracil
3ms
These findings support the hypothesis that LCL161 can inhibit proliferation and induce apoptosis in esophageal cancer cells by regulating the expression of IAP family members, suggesting that it has potential to be an effective treatment for esophageal squamous cell carcinoma.
Journal
|
BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • XIAP (X-Linked Inhibitor Of Apoptosis)
|
BAX expression
|
LCL161
3ms
In addition, C3G-DDP protected HeLa cells from oxidative stress-induced apoptosis by increasing bcl-2 levels and decreasing bax levels. These results expanded our understanding of the role of C3G in a cervical cancer cell model, and provided a potential new treatment strategy for this cancer, as well as a theoretical basis for the development of new drugs in the future.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • HMOX1 (Heme Oxygenase 1) • BAX (BCL2-associated X protein) • NQO1 (NAD(P)H dehydrogenase, quinone 1) • CAT (Catalase)
|
BCL2 expression • BAX expression • HMOX1 expression • KEAP1 expression
|
cisplatin
3ms
PTEN knockdown significantly attenuated the behavioral deficits in Barnes maze and fear conditioning tests, as well as over-expression of PTEN, AMPK, Bax, IL-1β, and TNF-α induced by surgery. PTEN knockdown could attenuate cognitive deficits induced by trauma, likely through inhibiting the activation of microglia.
Preclinical • Journal • IO biomarker
|
PTEN (Phosphatase and tensin homolog) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • IL1B (Interleukin 1, beta) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)
|
PTEN expression • BAX expression • AMPK expression
3ms
The levels of inflammatory factors and oxidative stress were also reduced by Lyc in the VaD models. We therefore conclude that Lyc can improve the learning and memory ability of VaD gerbils, the mechanism of which may be related to reduced oxidative stress and apoptosis in VaD hippocampus neurons.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • GFAP (Glial Fibrillary Acidic Protein)
|
BCL2 expression • BAX expression
3ms
LIPUS can improve the POF induced by VCD. These findings have the potential to provide novel methodological foundation for the future research, which help treat POF patients in the clinic.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
3ms
MS exhibit downregulation of anti-apoptotic BCL2 and increased expression of pro-apoptotic genes compared to PT. In contrast to evidence that metastatic PCa displays Bcl-2 overexpression and resistance to apoptosis, our suggest that MS are primed to apoptosis with site-specific expression profile of BCL2-related genes possibly regulated by microenvironment.
IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BAX (BCL2-associated X protein) • BAK1 (BCL2 Antagonist/Killer 1)
|
TP53 mutation • BCL2 overexpression • BCL2 expression • TP53 expression • BAX expression
|
MI Tumor Seek™
3ms
ZNF655 possessed a promoting effect in the progression of NSCLC, which may serve as a promising molecular target for clinical treatment.
Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CASP3 (Caspase 3) • CDK6 (Cyclin-dependent kinase 6) • CASP8 (Caspase 8) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BAX expression • CDKN1B expression
3ms
These results indicate that D-DT Tg overexpression confers prevention against UVB-induced apoptosis in keratinocytes. Taken together, these findings support D-DT as a functionally important cytokine in photocarcinogenesis and potential therapeutic target for the prevention of photocarcinogenesis.
Preclinical • Journal
|
BAX (BCL2-associated X protein) • MIF (Macrophage Migration Inhibitory Factor) • DCT (Dopachrome Tautomerase)
|
BAX expression
3ms
Moreover, the apoptosis rate was increased after the addition of the 3-MA inhibitor. NaF stimulation promoted autophagy and apoptosis of the osteoblasts, suggesting the involvement of fluoride damage in these processes.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • BECN1 (Beclin 1)
|
BCL2 expression • BAX expression
3ms
This study has elucidated that NCTD restrains NSCLC cell progression via regulation of AMPK/mammalian target of rapamycin (mTOR)/uncoordinated 51-like kinase 1 (ULK1)/JNK pathways. This evidence provides insight into a novel treatment for NSCLC.
Journal • IO biomarker
|
mTOR (Mechanistic target of rapamycin kinase) • MCL1 (Myeloid cell leukemia 1) • SQSTM1 (Sequestosome 1) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
3ms
HCT116 and SW620 cells were treated with oxaliplatin and MG132; oxaliplatin is a platinum compound that induces DNA damage and MG132 is a potent proteasome inhibitor. This process was associated with the Bcl‑2 and ubiquitin‑proteasome pathway. Overall, the present study provides a theoretical basis for improving the clinical efficacy of colon cancer by combining chemotherapy and gene therapy.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • MAD2L2 (Mitotic Arrest Deficient 2 Like 2)
|
BAX expression
|
oxaliplatin • MG132
3ms
Moreover, knockdown of EphA8 expression increased the chemosensitivity of BC cells to paclitaxel. In conclusion, the results of the present study indicated that EphA8 may be a useful prognostic marker in BC and that knockdown of EphA8 may represent a novel strategy in adjuvant chemotherapy for the treatment of BC.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • TP53 expression • BAX expression
|
paclitaxel
3ms
Also, the chemotherapeutic drug, Taxotere (Docetaxel), was employed to compare cytotoxicity effects...Meanwhile, the expression of angiogenesis and metastasis genes was decreased in both cell lines after treatment with either ARA-linker-TGFαL3 or Arazyme. Our in vitro results indicated the therapeutic effect of ARA-linker-TGFαL3 on breast cancer cells.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2) • KDR (Kinase insert domain receptor) • CASP3 (Caspase 3) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • TGFA (Transforming Growth Factor Alpha)
|
EGFR expression • BCL2 expression • EGFR negative • BAX expression
|
docetaxel
3ms
The overexpression of miR-183 can inhibit the drug resistance of the human primary laryngeal cancer cells to 5-Fu, promote cancer cell apoptosis and inhibit their invasive and migratory abilities at the same time, whose mechanism may be associated with the targeted regulation of the TBX3/PTEN signaling pathway by miR-183.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BAX expression
|
5-fluorouracil
3ms
LncRNA MALAT1 can promote the proliferation and invasion of glioma cells and inhibit the apoptosis of glioma cells by sponging miR-613. LncRNA MALAT1 can be applied as a new potential target for glioma treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1)
|
BAX expression
3ms
Consequently, it was revealed that the plant extract used had increased the gene expressions in the autophagic cell death pathway in C-4 I cells along with apoptosis and thus, it could be a promising candidate for cervix carcinoma treatment.
Preclinical • Journal
|
MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • CASP3 (Caspase 3) • ATG5 (Autophagy Related 5) • CASP7 (Caspase 7) • CASP9 (Caspase 9) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1) • ATG12 (Autophagy Related 12) • ATG7 (Autophagy Related 7) • BECN1 (Beclin 1)
|
BAX expression
3ms
In vivo, circCLSPN knockdown hindered tumor growth of LN18 cells by affecting miR-370-3p, USP39, MMP2 and MMP9 expression. In conclusion, circCLSPN elicited an oncogenic role in tumorigenesis and malignant progression of human GBM cells through circCLSPN-miR-370-3p-USP39 pathway.
Journal • IO biomarker
|
BAX (BCL2-associated X protein) • MMP2 (Matrix metallopeptidase 2) • MIR370 (MicroRNA 370) • MMP9 (Matrix metallopeptidase 9)
|
BCL2 expression • BAX expression • MMP9 elevation
3ms
Furthermore, knockdown of PYCR1 changed the expression of p-AKT and its target gene Cyclin D1. In conclusion, knockdown of PYCR1 inhibited the malignant phenotype of human HCC cells by regulating the AKT pathway activation, which provides a potential strategy for the human HCC therapy.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CASP3 (Caspase 3)
|
BCL2 expression • CCND1 expression • BAX expression
3ms
Fucoxanthin dose-dependently decreased ATP level and the total antioxidant capacity of PC-3 cells, increased the contents of HO, MDA and superoxide (all P < 0.05), enhanced the protein expressions of Bax and cytochrome c in the cytoplasm, and lowered the protein expressions of Bcl-2 and cytochromes in the mitochondria (P < 0.05). Fucoxanthin induces apoptosis of PC-3 cells by triggering mitochondrial dysfunction to cause oxidative stress and by activating mitochondria-mediated apoptotic signaling pathways, suggesting its potential in prostate cancer treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP7 (Caspase 7) • CASP9 (Caspase 9)
|
BCL2 expression • BAX expression
3ms
The studies may provide the scientific rationale for the understanding of the anticancer effect of atractylenolide III. Therefore, atractylenolide III may have the potential to be developed as a promising novel anticancer agent for the treatment of colorectal cancer clinically.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
BCL2 expression • TP53 expression • BAX expression
3ms
The results were further confirmed by immunofluorescence assays. Based on bioinformatic analysis and experimental verification, our findings demonstrated that tetrandrine exerted tumour-suppressive effects on EC by regulating the PI3K/Akt signalling pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
|
CBT-1 (tetrandrine)
3ms
All these phenomena consequent to CA IX inhibition triggered apoptosis and autophagy in HeLa cells. Taken together, these results further endorse the previous findings that CAIX inhibitors represent an important therapeutic strategy, which is worth pursuing in different cancer types, considering that presently only one sulphonamide inhibitor, SLC-0111, has arrived in Phase Ib/II clinical trials as an antitumour/antimetastatic drug.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CA9 (Carbonic anhydrase 9) • CASP12 (Caspase 12 (Gene/Pseudogene)) • CASP9 (Caspase 9)
|
BCL2 expression • BAX expression
|
SLC-0111
3ms
The therapeutic effects were demonstrated to be dose dependent. In conclusion, the findings of the study showed that ETSJC improved the chemosensitivity of 5-FU by blocking Notch1/Hes1 signaling pathway in gastric cancer-bearing mice.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • NOTCH1 (Notch 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CD31 (Platelet and endothelial cell adhesion molecule 1) • HES1
|
BCL2 expression • BAX expression • CD31 expression • NOTCH1 expression
|
5-fluorouracil
3ms
Aspirin eugenol ester (AEE) is a new pharmaceutical compound esterified by aspirin and eugenol, which has anti-inflammatory, antioxidant, and other pharmacological activities. The silencing of PI3K with shRNA and its inhibitor-LY294002 could abrogate the protective effect of AEE in PC12 cells. Therefore, AEE has a protective effect on HO-induced PC12 cells by regulating the PI3K/Akt signal pathway to inhibit oxidative stress.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CAT (Catalase)
|
BCL2 expression • BAX expression
|
quercetin (LY294002) • aspirin
3ms
Our findings indicated that LINC00942/miR-5006-5p/FZD1 axis played important roles in LUAD growth through enhancing Wnt signaling. LINC00942/miR-5006-5p/FZD1 axis might serve as a potential biomarker and therapeutic target for LUAD treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • PCNA (Proliferating cell nuclear antigen)
|
BCL2 expression • BAX expression • PCNA expression
3ms
The results of our study suggested that SCU promotes the anticancer effects induced by I in NSCLC cells by downregulating the AKT/mTOR pathway and lays a foundation for future application of this combined treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
3ms
Moreover, the tumor-infiltrating lymphocytes from tumor-bearing mice were analyzed by flow cytometry, and showed that TIPE2 could promote T cell activation to exert an anti-tumor effect possibly through activation of DCs in a TGFβ1 dependent manner. In general, we described the multiple regulatory mechanisms of TIPE2 in pancreatic tumorigenesis and tumor microenvironment, which suggested TIPE2 may act as a potential therapeutic target in pancreatic cancer.
Journal
|
BAX (BCL2-associated X protein) • TGFB1 (Transforming Growth Factor Beta 1)
|
BAX expression
3ms
The miR-125b regulates the expression of Bax and Bcl-2 by downregulating the expression of STAT3, thereby inhibiting proliferation and inducing apoptosis of SW480 colon cancer cells.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
BCL2 expression • BAX expression • STAT3 expression • miR-125b overexpression
3ms
The combination treatment with CM and ponesimod reduced the expression of caspase-3, caspase-8, Bax, and Annexin V proteins and increased the relative BCL-2/Bax ratio, indicating inhibition of apoptosis as a possible mechanism of action. Based on these promising results, combination therapy with amniotic stem cells and ponesimode could be a proper alternative for multiple sclerosis treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP8 (Caspase 8)
|
BAX expression • BCL2/BAX ratio elevation
|
Ponvory (ponesimod)
3ms
However, quenching of ROS by N-acetyl-cysteine, an ROS scavenger, markedly abolished BA-induced G2/M arrest and apoptosis, indicating that the generation of ROS plays a key role in inhibiting the proliferation of U937 cells by BA treatment. Taken together, our results provide a mechanistic rationale that BA exhibits anti-cancer properties in U937 leukemia cells through ROS-dependent induction of cell cycle arrest at G2/M phase and apoptosis.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CCNA2 (Cyclin A2) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP9 (Caspase 9) • CCNB1 (Cyclin B1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BCL2 expression • BAX expression
3ms
Kaempferol has the capability of attenuating H9C2 cells IR injury through activating SIRT3 to inhibit oxidative stress.
Journal • IO biomarker
|
BAX (BCL2-associated X protein) • SIRT3 (Sirtuin 3)
|
BCL2 expression • BAX expression
3ms
Our findings revealed that Rau repressed CRC cell viability and autophagy in vitro and in vivo, suggesting that Rau might be a potent therapeutic agent of CRC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
3ms
These findings clearly indicated that metformin plus pitavastatin had a synergistic anticancer effect on pancreatic cancer cells, potentially caused due to the activation of AMPK and inhibition of PI3K/mTOR signaling. Altogether, our results provide that use of metformin plus pitavastatin maybe serve as a chemotherapeutic agent for human pancreatic cancer in future.
Journal • PARP Biomarker
|
BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PCNA (Proliferating cell nuclear antigen) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BAX expression • PARP1 expression • CDKN1B expression • PCNA expression
|
metformin • Livalo (pitavastatin)
3ms
We found that cell proliferative potential was notably increased in the interfering group compared with the negative and untreated group. What's more, MT2A may be closely related to AML cell proliferation and function via the NF-κB signal pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BAX (BCL2-associated X protein)
|
BCL2 expression • CCND1 expression • BAX expression
3ms
Rac1 and Cdc42 could regulate mTOR to inhibit autophagy and apoptosis in RMS. Overall, these studies demonstrated that the GEFT-Rac1/Cdc42-mTOR pathway can inhibit autophagy and apoptosis in RMS and provide evidence for innovative treatments.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • BECN1 (Beclin 1)
|
BCL2 expression • BAX expression
3ms
Western blotting showed that compared to that of cells treated with Notch2 overexpression or radiotherapy alone, the levels of γH2AX, Bax, Bcl-2, Cyclin D1 and AKT/mTOR signaling pathway-related proteins were modified in NPC cells overexpressing Notch2 and treated with radiotherapy. These findings showed that overexpression of Notch2 can increase the radiosensitivity of NPC cells by inhibiting the AKT/mTOR pathway.AbbreviationsNPC: Nasopharyngeal carcinoma; EMT: Epithelial-mesenchymal transition; CCK8: Cell counting kit-8; EBV: Epstein-Barr virus; FBS: Fetal bovine serum; PE: Plating efficiency; SF: Survival fraction; SER: Sensitizing enhancement ratio; DSBs: DNA double-strand breaks&lsqb;Figure: see text].
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • NOTCH2 (Notch 2) • BAX (BCL2-associated X protein)
|
BAX expression
3ms
The percentage area of the glial fibrillary acidic protein significantly increased, whereas that of caspase-3 significantly decreased. In conclusion, SeNPs have an ameliorative effect against melamine-induced neurotoxicity in albino rats.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • GFAP (Glial Fibrillary Acidic Protein)
|
BAX expression
3ms
Our findings support the therapeutic potential of this potent RAS signaling inhibitor either alone or in combination with standard regimens for the management of patients with CRC.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase) • CDH1 (Cadherin 1) • CD31 (Platelet and endothelial cell adhesion molecule 1)
|
KRAS mutation • CDH1 expression • TP53 expression • BAX expression • CD31 expression
|
5-fluorouracil • Estybon (rigosertib)
4ms
Furthermore, rapamycin markedly reversed the effects of ozone (20 µg/ml) on OGD/R-induced expression of autophagy marker proteins and 3-methyladenine further improved the effect of ozone. Taken together, the results of the present study provided a credible mechanism by which ozone treatment at low concentrations could protect the myocardium from OGD/R-induced injury by inhibiting autophagy.
Journal • IO biomarker
|
CASP3 (Caspase 3) • ATG5 (Autophagy Related 5) • BECN1 (Beclin 1)
|
BCL2 expression • BAX expression • ATG5 expression
|
sirolimus
4ms
Oridonin augmented all the effects of LNT on expression of these proteins in the cells. Together, the results showed that oridonin enhanced the antitumor effects of LNT, and may thus serve as an adjuvant alongside LNT as a novel anticancer regimen for treatment of lung cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BCL2 expression • BAX expression
4ms
miR-26b-5p inhibitor transfection partially reversed the effects of HAGLROS knockdown on the proliferation and apoptosis of OV cells. In conclusion, the results of the present study suggested that interference of HAGLROS suppressed the proliferation and promoted the apoptosis of OV cells through regulating miR-26b-5p, indicating that HAGLROS may be a promising biomarker in OV diagnosis and treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
4ms
ME downregulated STAT1, 3, and 5B in HT-29 cells. The D. calcarata bulb extracts, therefore, contain potential anticancer agents that can be further targeted for cancer therapeutics.
Preclinical • Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • BAX (BCL2-associated X protein) • STAT1 (Signal Transducer And Activator Of Transcription 1)
|
TP53 mutation • BAX expression
4ms
Our findings also revealed that Sodium Danshensu inhibited PI3K/AKT pathway in A549 and NCI-H1299 cells. In conclusion, our study provided the first evidence that Sodium Danshensu suppressed the malignant biological behaviors of lung cancer cells, indicating that Sodium Danshensu might be a latent candidate for lung cancer therapy.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen)
|
BCL2 expression • BAX expression • PCNA expression
4ms
Furthermore, the Notch pathway activator Jagged-1/FC reversed the effects of palbociclib on cell proliferation, apoptosis, senescence and cell cycle progression. These findings demonstrated that palbociclib could inhibit proliferation and induce senescence, cell cycle arrest and apoptosis in GC cells by inhibiting the Notch pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • NOTCH1 (Notch 1) • NOTCH2 (Notch 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • HES1 • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BCL2 expression • BAX expression • NOTCH1 expression
|
Ibrance (palbociclib)
4ms
In conclusion, the present study demonstrated that miR-744-5p targets RFC2 and suppresses the progression of GBM by repressing cellular proliferation, migration and Bcl-2 protein expression, and effectively promoting caspase-3 activity and Bax protein expression. These findings suggest a new target for the clinical treatment and improved prognosis of patients with GBM in the future.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
4ms
The combination of apigenin and doxorubicin inhibited PI3K and AKT phosphorylation more strongly than a single administration. Our data indicate that a combination of the natural flavone apigenin with doxorubicin might have a potential in treatment of castration-resistant prostate cancer.
Journal
|
PTEN (Phosphatase and tensin homolog) • BCL2L1 (BCL2-like 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
PTEN expression • BAX expression • CDKN1B expression
|
doxorubicin hydrochloride
4ms
Piperine (20 μM) and cisplatin (5 μM) for 24 h induce apoptosis strongly through reduction of Bcl-2 and increase of caspase 3, p53, caspase 9, and Bax. Piperine in combination with cisplatin could trigger p53-mediated apoptosis more effective than cisplatin alone in MCF-7 breast cancer cells, reducing the toxic dose of cisplatin used in cancer chemotherapy.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
TP53 expression • BAX expression
|
cisplatin
4ms
Collectively, we suggest that RNF19A plays a critical oncogenic role in lung carcinogenesis by disrupting the function of p53. RNF19A may serve as a new biomarker and/or target for NSCLC management.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • BAX (BCL2-associated X protein) • CDK6 (Cyclin-dependent kinase 6) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BCL2 expression • CCND1 expression • BAX expression • CDK6 expression
4ms
In addition, radotinib significantly suppressed MM cell growth in a xenograft animal model using RPMI-8226 cells, and killed ex vivo myeloma cells from patients. In conclusion, radotinib may play an important role as a candidate agent or chemosensitizer for the treatment of MM.
Journal • PARP Biomarker • IO biomarker
|
ABL1 (ABL proto-oncogene 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • KIT expression • BAX expression • PARP1 expression
|
Supect (radotinib)
4ms
S. costus may prevent and treat BPH occurrence by modulating inflammation and apoptosis imbalance.
Journal • IO biomarker
|
BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
4ms
The expression of LC3, Bax and Bcl-2 changes in the periodontal tissue of diabetic rats may indicate that autophagy and apoptotic are involved in the process of periodontal tissue damage in diabetic rats. These changes may be one of the mechanisms of periodontal tissue lesions.
Preclinical • Journal • IO biomarker
|
BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
4ms
Our data indicate the potential cytotoxic effects of 5-ALA on U87MG cells. Further studies are required to determine the spectrum of the antitumor activity of 5-ALA on GBM.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BAX (BCL2-associated X protein)
|
BCL2 expression • CCND1 expression • TP53 expression • BAX expression
4ms
SNHG1 interacts with miR-216a-3p to regulate the expression of BAX. This SNHG1/miR-216a-3p/BAX molecular regulatory network is implicated in the pathogenesis of PD.
Journal • IO biomarker
|
BAX (BCL2-associated X protein) • MIR216A (MicroRNA 216a)
|
BAX expression
4ms
Western blot analysis revealed that spermine increased the expression of pro-caspase9, phosphorylated protein kinase B (p-Akt), hypoxia-inducible factor 1 alpha (HIF-1α), B cell lymphoma 2 (Bcl-2), and Bcl2 interacting protein 3 (BNIP3), and decreased the expression of cleaved caspase-3, Bax and cytochrome C compared to control cells. Exogenous spermine exerted a protective effect on renal ischemia-reperfusion injury in rats by inhibiting the apoptosis of renal tubular epithelial cells.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CASP3 (Caspase 3) • KIM1 (Kidney injury molecule 1) • LCN2 (Lipocalin-2) • BNIP3 (BCL2 Interacting Protein 3)
|
BAX expression • HIF1A expression
4ms
By western blot assay, we found that devazepide can down-regulate CyclinD1 expression, and up-regulate Bax, PARP1, and Cleaved Caspase-3 expression. Devazepide inhibits the migration and proliferation of human BC 5637 cells by arresting the G1-S cell cycle, and induces cell apoptosis.
Journal • PARP Biomarker • IO biomarker
|
CCND1 (Cyclin D1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • CCND1 expression • BAX expression • PARP1 expression
4ms
In conclusion, this study suggested that ARHGAP9 interference exerted an anti-tumor effect through inhibiting cell proliferation, blocking cell cycle progression, and promoting cell apoptosis in AML cells. ARHGAP9 may serve as a novel therapeutic target for AML.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • CDK4 (Cyclin-dependent kinase 4) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CDK6 (Cyclin-dependent kinase 6) • CASP9 (Caspase 9) • PCNA (Proliferating cell nuclear antigen) • SOX4 (SRY-Box Transcription Factor 4)
|
BCL2 expression • BAX expression
4ms
The results of our study suggest that inhibiting TLR9 signaling might be an interesting therapeutic intervention for the treatment of cervical cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • BAX (BCL2-associated X protein) • VCAM1 (Vascular Cell Adhesion Molecule 1) • CDC25A (Cell Division Cycle 25A) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
|
BCL2 expression • CCND1 expression • BAX expression • VEGFA expression • CDKN1B expression
4ms
Thus, RES-NLC-gel exhibited an obvious anti-UV irradiation and anti-oxidant activity in vivo. RES-NLC-gel displayed great application potential in protecting skin from UV irradiation.
Clinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CAT (Catalase)
|
BCL2 expression • BAX expression
4ms
In addition, GC-MS analysis detected 17 potential anticancer components in R. molle. These results indicate that R. molle has significant anticancer activity, which provides some useful information for further study and clinical application for R. molle.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BCL2 expression • TP53 expression • BAX expression
4ms
As a hallmark of apoptosis, the expression ratio of BAX/BCL-2 was significantly increased in all treated cells. Taken together, our findings demonstrated that Gemini-Cur suppresses the proliferation of cancer cells via induction of apoptosis and could be considered as novel nano-formulated phytochemical for cancer targeting.
Preclinical • Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
TP53 mutation • BCL2 expression • TP53 expression • BAX expression
4ms
Concomitantly, pretreatment with NAC reversed the effect of gastrin on the Bax and Bcl-2 expression. Gastrin promotes the production of ROS from mitochondria, activates NF-κB, and inhibits apoptosis via modulating the expression level of Bcl-2 and Bax.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • RELA (RELA Proto-Oncogene) • GAST (Gastrin 2)
|
BCL2 expression • BAX expression
4ms
This study revealed the mechanisms by which pemetrexed works an anticancer drug in the treatment of NSCLC.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP9 (Caspase 9) • FASLG (Fas ligand)
|
EGFR exon 19 deletion • BCL2 expression • BAX expression
|
pemetrexed
4ms
Raddeanin A suppressed the proliferation and induced apoptosis of NSCLC cells via promoting the ROS-mediated STAT3 inactivation.
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3)
|
BAX expression
4ms
In in vivo experiments, Bupivacaine inhibited tumor volume and tumor, as well as NF-κB expression. In short, bupivacaine is available to inhibit CRC proliferation through regulating NF-κB signaling pathway, promote apoptosis and autophagy, and can be used as a potential drug to treat CRC in the future.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta) • BECN1 (Beclin 1)
|
BCL2 expression • BAX expression
4ms
Additionally, in this group, the number of invasive and migratory cells remarkably reduced; the expression of invasion-related protein E-cadherin remarkably rose but that of MMP-2 remarkably reduced; cell cycles were arrested and the expression of cycle-related proteins (CDK4, CDK6, cyclin D1) remarkably reduced; the apoptotic rate and the expression of apoptosis-related protein Bax remarkably rose. LncRNA NCK1-AS1 is highly expressed in PCa, so its down-regulation can inhibit PCCs from proliferating and reduce the number of invasive cells.
Journal
|
CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDH1 (Cadherin 1) • CDK6 (Cyclin-dependent kinase 6) • MMP2 (Matrix metallopeptidase 2)
|
CCND1 expression • CDH1 expression • BAX expression • CDK6 expression
4ms
These above expressions were partially reversed by miR-326 overexpression. CircHIPK3 sponges miR-326 to promote BCa growth and metastasis. The current findings provide a novel therapeutic target for treating BCa.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • CASP3 (Caspase 3) • VIM (Vimentin)
|
BCL2 expression • CDH1 expression • BAX expression • VIM expression
4ms
In addition, BA triggered a dose-dependent cytotoxic effect characterized by apoptotic features: morphological alterations (nuclear fragmentation, apoptotic bodies) and the upregulation of pro-apoptotic markers mRNA expression (Bax, Bad and Bak). BA represents a viable therapeutic option via a complex modulatory effect on mitochondrial metabolism that might be useful in advanced melanoma or as reliable strategy to counteract resistance to standard therapy.
Preclinical • Journal
|
BAX (BCL2-associated X protein)
|
BAX expression
4ms
Competitive antagonist of transmembrane glutamine flux V-9302 can significantly promote the apoptosis of acute myeloid leukemia cell lines HL-60 and KG-1.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
4ms
TRIM31 gene silencing can inhibit U266 cell proliferation and promote its apoptosis, which may be closely related to inhibition of PI3K/Akt signaling pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
|
quercetin (LY294002)
4ms
TRB3 regulates hepatocarcinoma cells proliferation, apoptosis and migration by inhibiting the AKT phosphorylation activity. Therefore, TRB3 may be a potential target site for the liver cancer treatment.
Journal
|
MMP9 (Matrix metallopeptidase 9) • TRIB3 (Tribbles Pseudokinase 3)
|
BAX expression
4ms
COE can significantly promote apoptosis of human gastric cancer cells, which can be achieved by inhibiting PHB expression, thus altering the structure and function of mitochondria and activating the mitochondria apoptosis pathway. The antitumor effect of COE has also been proved in vivo.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
4ms
miR-145-5p inhibited the luciferase activity of IU-TAB-1 cells transfected with the MALAT1 or HMGA2 3' untranslated region. In conclusion, si-MALAT1 significantly attenuated cell proliferation and apoptosis via the miR-145-5p/HMGA2 pathway in thymic cancer cells.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BAX (BCL2-associated X protein) • MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • HMGA2 (High mobility group AT-hook 2)
|
BCL2 expression • CCND1 expression • BAX expression
4ms
Following cell transfection and grouping, an MTT assay detected the activity of NSCLC cells, a scratch wound test assessed the migration ability, flow cytometry using PI staining detected the cell cycle phase, TUNEL and flow cytometry through Annexin V-PI staining assessed the apoptosis, and colony formation was used to detect the sensitivity of lung cancer cells to cisplatin chemotherapy...In addition, compared with the control group, the siBRAF, NVP-BEZ235 and siBRAF + NVP-BEZ235 groups had significant decreased cell viability at 2-6 days, decreased migration ability, shortened proportion of S-phase cells, increased proportion of G/G-phase cells, increased apoptosis rate, decreased number of colony-forming cells, decreased mRNA expression of PI3K, Akt and mTOR, increased PTEN mRNA expression, decreased protein expression levels of PI3K, p-PI3K, Akt, p-Akt, mTOR, p-mTOR, ERCC1, BRCA1 and Bcl-2, and increased protein expression levels of PTEN and Bax (all P<0.05); and more obvious trends were revealed in the siBRAF + NVP-BEZ235 group (all P<0.05); whereas opposite results were detected in the siBRAF + IGF-1 group when compared with the siBRAF group and NVP-BEZ235 group (all P<0.05)...Activation of the PI3K/Akt/mTOR signaling pathway may reverse the role of silencing of BRAF gene expression, providing a potential approach for improving the chemosensitivity of NSCLC. The present study for the first time, to the best of our knowledge, clarified the possible mechanism of NSCLC cell biological characteristic changes and chemosensitivity from the perspective of BRAF gene silencing and PI3K/Akt/mTOR signaling pathway activation, providing a potential reference for suppressing tumor aggravation and improving the therapeutic outcomes of NSCLC at the genetic level.
Journal • BRCA Biomarker • IO biomarker
|
BRAF (B-raf proto-oncogene) • BRCA1 (Breast cancer 1, early onset) • PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • ERCC1 (Excision repair cross-complementation group 1) • IGF1 (Insulin-like growth factor 1) • BAX (BCL2-associated X protein)
|
PTEN expression • BAX expression
|
cisplatin • dactolisib (RTB101)
4ms
Moreover, knocking down PRMT5 could weaken the tumor growth and lung metastasis in vivo with upregulating the LKB1 expression and the p-AMPK level and downregulating the p-mTOR expression. PRMT5 may act as a tumor-inducing agent in ESCC by modulating LKB1/AMPK/mTOR pathway signaling.
Journal
|
BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • MMP2 (Matrix metallopeptidase 2) • PRMT5 (Protein Arginine Methyltransferase 5) • CASP9 (Caspase 9) • MMP9 (Matrix metallopeptidase 9) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BAX expression • STK11 expression • AMPK expression
4ms
In CRC HT-29 cells, Scutellarin retarded the proliferation and migration, induced apoptosis, with boosted Bax expression and decreased Bcl-2 level, which may be attributed to its repression of Wnt/β-catenin signals in HT-29 cells. Our findings demonstrate that Scutellarin may ameliorate colitis-associated colorectal cancer by weakening Wnt/β-catenin signaling cascade.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression • IL6 expression
4ms
This study demonstrates that ECH exerts anti-tumor activity via the miR-503-3p/TGF-β1/Smad aixs in liver cancer, and provides a safe and effective anti-tumor agent for liver cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • TGFB1 (Transforming Growth Factor Beta 1) • MIR503 (MicroRNA 503) • SMAD7 (SMAD Family Member 7) • SMAD3 (SMAD Family Member 3)
|
BCL2 expression • BAX expression • miR-503 expression
4ms
In addition, miR-448-5p mimic inhibited the effect of hypoxia on promoting the expressions of FAS and FAS-L of H9C2 cells. Inhibitors had the opposite effect on cell hypoxia model.The miR-448-5p/VEGFA axis could protect cardiomyocytes from hypoxia through inhibiting the FAS/FAS-L signaling pathway.
Journal • IO biomarker
|
CASP3 (Caspase 3)
|
BCL2 expression • BAX expression • FASN-L • VEGFA expression
4ms
In these investigations, decreased cell viability (14.22 ± 0.3% after 72 h treatment), increased apoptotic and autophagy-related genes expression level (BECLIN1: 34-folds, BAX: 36-folds, mTORC1: 10-folds, and Caspase-9: 9-folds more than control), higher cell cycle arrest in sub-G1 phase (19.53% of cells in sub-G1 phase), and more apoptosis analyses (late apoptosis: 67.7%) were evaluated in colon cancer cells treated with MCFL224 nano-complex. Results remarkably indicate the inhibited growth of colon cancer cells and induced cell apoptosis which suggests MCFL224 as a promising nanocomposite for colon cancer therapy.
Preclinical • Journal
|
CASP9 (Caspase 9) • BECN1 (Beclin 1)
|
BAX expression
4ms
Mechanistic studies revealed that the synergistic antiproliferative activity depends primarily on the induction of cell apoptosis and senescence but not cell cycle arrest. Our findings provide strong evidence that three novel HPV16 E6-binding affibody molecules could form a novel basis for the development of rational strategies for molecular imaging and targeted therapy in HPV16-positive preneoplastic and neoplastic lesions.
Journal
|
TP53 (Tumor protein P53) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
TP53 expression • BAX expression
4ms
MiR-409-3p knockdown weakened HO-induced proliferation reduction and apoptosis promotion via regulating MCL1. Circ_DOCK1 overexpression mitigated HO-caused proliferation inhibition and apoptosis promotion in HBVSMCs by modulating miR-409-3p/MCL1 axis.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • MIR409 (MicroRNA 409) • PCNA (Proliferating cell nuclear antigen)
|
BCL2 expression • MCL1 expression • BAX expression • PCNA expression
4ms
Pseudo-G-Rh2 could induce protective autophagy in HepG2 cells, at least in part, via AMPK and the PI3K/Akt/mTOR pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • BECN1 (Beclin 1)
|
BCL2 expression • BAX expression
4ms
Further, in silico studies have also supported our in vitro findings by exhibiting significant binding energy against selected target oncoproteins. Therefore, our research findings might recommend rutin as one of the potent drug candidate in cervical cancer management via targeting two crucial oncoproteins associated with viral progression.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9)
|
BCL2 expression • TP53 expression • BAX expression
4ms
Based on the results, presently investigated phyto-compound vitexin could be considered for developing safe and natural drugs to treat leukemia after conducting suitable preclinical and clinical trials.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • CASP9 (Caspase 9)
|
BAX expression
4ms
Taken together, these findings imply new insights into the regulatory network of the Wnt pathway through lncRNA ANRIL that indicate ANRIL may be a therapeutic factor potential for hepatocellular carcinoma.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BAX expression
4ms
In addition, NaB substantially reversed the reactive oxygen species in HO induced SH-SY5Y cells. Altogether, our results suggest that sodium butyrate has potential therapeutic effects against NDDs.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • SOD2 (Superoxide Dismutase 2)
|
BAX expression
4ms
SKOV-3 and OVCAR-3 cells (1 × 105/ml) were cultured in DMEM medium and treated with exendin-4 in the presence or absence of chloroquine (CQ), an autophagy inhibitor. Moreover, only the combined treatment with IGF-1 and CC completely abolished the observed effect of exendin-4 on the expression of beclin-1, LC3I/II, p62, as well as on cell survival, apoptosis, and LDH release. Exendin-4 exhibits a potent anti-tumour cytotoxic effect in SKOV-3 and OVCAR-3 cells by activating the markers of autophagy, mediated by activation of AMPK and inhibition of Akt.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IGF1 (Insulin-like growth factor 1) • CASP8 (Caspase 8) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • BECN1 (Beclin 1)
|
BAX expression
|
Byetta (exenatide) • chloroquine phosphate
4ms
MiR-488 inhibited neural inflammation and apoptosis in SCI via its binding with HMGB1-mediated restraint on the TLR4/NF-κB signaling pathway.
Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • HMGB1 (High Mobility Group Box 1) • TLR4 (Toll Like Receptor 4) • IL1B (Interleukin 1, beta)
|
BCL2 expression • BAX expression
4ms
After BAY11-7082 treatment alone, Bcl2, BAX, c-caspase-3, NF-κB p65 protein expression trend was consistent with that of the 300 mmol/L BET treated group, and Bcl2, NF-κB p65 protein expression levels were lower and BAX and c-caspase-3 protein expression levels were higher in BET combined with BAY11-7082 treated group. Conclusion BET can inhibit C4-2B cell proliferation and induce its apoptosis by blocking PI3K/AKT/NF-κB signaling pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • RELA (RELA Proto-Oncogene)
|
BCL2 expression • BAX expression
|
Bay11-7082
4ms
In addition, we found that using a COX-2 inhibitor, celecoxib, could enhance the anti-metastatic role of miR-30a-3p in MHCC-97H cells. Lastly, we found that decreased COX-2 protein level affected PGE2 production, leading to lower Bcl-2, Caspase-3, MMP2 and MMP9 expression but higher Bax and E-cadherin expression, which in turn culminated in higher rates of cell death and lower rates of cell migration. Taken together, our findings demonstrate that miR-30a-3p could be a target for the treatment of hepatocellular carcinoma cells progression.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
CDH1 expression • BAX expression • PTGS2 expression
|
celecoxib oral
4ms
Overexpression of SIRT1 could reduce anti-proliferative and pro-apoptotic effects of miR-373. Overall, this study concluded that miR-373-dependent SIRT1 inhibition displays anti-proliferative and proapoptotic roles in PC cells via PGC-1α/NRF2 pathway, which highlights miR-373 as a potential target for PC treatment.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • NOS3 (Nitric oxide synthase 3)
|
BCL2 expression • BAX expression
4ms
We demonstrated that Gem combined HY-PDT could inhibit the proliferation of Capan-2 cells and induce cell apoptosis. HY-PDT combined with Gem had a great potential on pancreatic cancer treatment clinically.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression • BAX expression
|
gemcitabine
4ms
Our data showed a synergistic inhibitory effect of MH on DOX-mediated apoptotic cell death in HCC cells. To our knowledge, the present study provides the first report on the anticancer activity of MH and its combined treatment with DOX on HCC cell lines, introducing MH as a promising natural and nontoxic anticancer compound.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CASP3 (Caspase 3) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
|
BCL2 expression • BAX expression
|
doxorubicin hydrochloride
4ms
Usm and Sil increased BAX expression, Met and Sil induced CASPASE 9 expression, and Usm increased TNFR1. Colombian propolis samples exhibited cytotoxic and apoptotic effects on canine OSA cells, and CASPASE 8 upregulation indicated apoptosis induction by the extrinsic pathway.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP8 (Caspase 8) • FUS (FUS RNA Binding Protein) • CASP9 (Caspase 9)
|
BCL2 expression • MET expression • BAX expression
4ms
DC-induced antiproliferation, colony formation, anti-migration, and anti-invasion were associated with the suppression of Akt/mTOR/cyclin D1 and FAK signaling pathways. These findings suggest that the multi-targeting strategies with DC may be a novel treatment for cancer therapy.
Journal
|
TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
TP53 expression • BAX expression
4ms
Gas chromatography-mass spectrometry analysis (GC-MS) analysis showed that the major compounds found in DF-CME-MOL were benzeneacetonitrile, 4-hydroxy- and benzeneacetic acid, 4-hydroxy-, methyl ester among others that were detected. Thus, DF-CME-MOL extract was found to inhibit the proliferation of MCF7 cells by apoptosis induction, which is likely due to the activities of the detected phytochemical compounds of the extract.
Journal
|
BAX (BCL2-associated X protein) • CASP8 (Caspase 8)
|
BAX expression
4ms
The expression of bcl-2 in LGPA lesion tissues was dramatically higher (P<0.001), the expression of bax was not significantly different between groups (P=0.25), but the ratio of bcl-2/bax was significantly higher in tumor tissues (P=0.01). CONCLUSIONS We found that the lacrimal gland tumor tissues had obvious excessive proliferation in pathomorphology, which revealed the necessity of complete surgical removal of the capsule from the perspective of pathological morphology and provided a theoretical basis for the hypothesis that the imbalance between apoptosis and proliferation could lead to cell hyperproliferation.
Retrospective data • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
4ms
Knockdown of miR-499a-5p suppressed AML cell proliferation and promoted AML cell apoptosis, but silencing PDCD4 abolished this effect. LINC01018 inhibited AML cell growth by modulating PDCD4 through suppression of miR-499a-5p, providing a feasible theoretical basis for the treatment of AML.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
4ms
Moreover, the effects of RPMTG on cell proliferation and apoptosis were partially reversed when the JNK and p38 mitogen‑activated protein kinase (MAPK) pathways were inhibited, indicating that RPMTG triggered apoptosis mainly via regulating JNK and p38 MAPK signalling. Therefore, RPMTG may have potential as an anti‑CRC agent, and further evaluations are needed.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • MAPK8 (Mitogen-activated protein kinase 8)
|
BCL2 expression • BAX expression
5ms
Collectively, we report the antimetastasis potential of biogenic synthesized AgNPs against breast and colorectal cancers. The biogenic synthesis of AgNPs seems to be a promising anticancer therapy with greater efficacy against the studied cell lines.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
TP53 expression • BAX expression
5ms
Melittin suppresses the expression of genes responsible for formation of TME physiological hallmarks by suppressing HIF-1α signaling pathway. Our results suggest that Melittin can modulate tumor microenvironment by inhibition of VEGFA and LDHA.
Journal
|
LDHA (Lactate dehydrogenase A) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein)
|
BAX expression • HIF1A expression
5ms
The expression level of miR-505-5p is raised significantly in the cancer tissues of osteosarcoma patients, and the inhibition of miR-505-5p can up-regulate RASSF8 to suppress the proliferation and promote the apoptosis of osteosarcoma cells.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
5ms
Bismahanine exhibits significant anti-proliferative effects on the cervical cancer cells and may prove essential in the development of chemotherapy for cervical cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
BCL2 expression • BAX expression
5ms
Furthermore, we also noticed increased expression of Bcl-2, decreased expressions of bax, cleaved caspase 3 and cleaved PARP, promoted cell survival-related protein p53, and reduced survivin. CONCLUSIONS This study demonstrated that knockdown of CHI3L1 inhibits cancer cell proliferation by regulating cell cycles, promotes cancer cell apoptosis, and enhances the pro-apoptotic effect of anti-PD-L1 antibody both in vivo and in vitro in DLBCL.
Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BIRC5 (Baculoviral IAP repeat containing 5) • CASP3 (Caspase 3) • CCND2 (Cyclin D2) • CHI3L1 (Chitinase 3-like 1)
|
BCL2 expression • CCND1 expression • BAX expression
5ms
The present study revealed that silibinin shows anticancer activities by targeting proliferation, cell survival, angiogenesis, and migration of CT26 cells.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • MMP2 (Matrix metallopeptidase 2) • ATG5 (Autophagy Related 5) • MMP9 (Matrix metallopeptidase 9) • ATG7 (Autophagy Related 7) • BECN1 (Beclin 1)
|
BAX expression • HIF1A expression • PTGS2 expression
|
Legalon (silibinin)
5ms
Taken together, the results of this study showed for the first time that Britannin, as a natural Sesquiterpene Lactone, has cytotoxic effects that could be considered as an anti-leukemic agent in the treatment of ALL. However, there is still a demand for further studies that examine the efficacy and the safety of this purified compound.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • XIAP (X-Linked Inhibitor Of Apoptosis) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BCL2 expression • BAX expression
|
vincristine
5ms
CNPY2 alleviates oxidative stress, mitochondria dysfunction, and apoptosis of neurons induced by MPP+ by activating the AKT/ GSK3β signaling pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • GSK3B (Glycogen Synthase Kinase 3 Beta)
|
BAX expression
|
MK-2206
5ms
Moreover, GHI administration inhibited the activation of the PI3K/AKT signaling pathway in rat brain microvascular endothelial cells (rBMECs) following oxygen/glucose deprivation (OGD) injury. Therefore, our results show that GHI administration resulted in antiapoptosis of cerebral cells and repair of cerebral microvessels and mitochondria via the PI3K/AKT signaling pathway.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • TGFB1 (Transforming Growth Factor Beta 1) • MMP9 (Matrix metallopeptidase 9)
|
BCL2 expression • BAX expression • VEGFA expression
5ms
Furthermore, caspase-3, -8, -9 up-regulation was related to the apoptotic effect of δ-tocotrienol; therefore, δ-tocotrienol triggers apoptosis in CNE1 cells through caspase-3 signaling. δ-Tocotrienol may potentially be developed as an anti-cancer agent in the management of nasopharyngeal carcinoma.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9)
|
BCL2 expression • BAX expression
5ms
Significantly, pemetrexed induced cytotoxicity without inhibiting the RAS/RAF/MEK/ERK signaling pathway, while pemetrexed induced autophagy, which activated the AMPK/mTOR signaling pathway. Conclusion Taken together, these findings indicate that, in addition to apoptosis, pemetrexed-induced autophagy and cellular senescence, providing a promising direction for the development of KRAS-targeted therapy.
PARP Biomarker
|
KRAS (KRAS proto-oncogene GTPase) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
KRAS mutation • BAX expression
|
pemetrexed
5ms
Significantly, pemetrexed induced cytotoxicity without inhibiting the RAS/RAF/MEK/ERK signaling pathway, while pemetrexed induced autophagy, which activated the AMPK/mTOR signaling pathway. Conclusion Taken together, these findings indicate that, in addition to apoptosis, pemetrexed-induced autophagy and cellular senescence, providing a promising direction for the development of KRAS-targeted therapy.
PARP Biomarker
|
KRAS (KRAS proto-oncogene GTPase) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
KRAS mutation • BAX expression
|
pemetrexed
5ms
Significantly, pemetrexed induced cytotoxicity without inhibiting the RAS/RAF/MEK/ERK signaling pathway, while pemetrexed induced autophagy, which activated the AMPK/mTOR signaling pathway. Conclusion Taken together, these findings indicate that, in addition to apoptosis, pemetrexed-induced autophagy and cellular senescence, providing a promising direction for the development of KRAS-targeted therapy.
PARP Biomarker
|
KRAS (KRAS proto-oncogene GTPase) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
KRAS mutation • BAX expression
|
pemetrexed
5ms
Significantly, pemetrexed induced cytotoxicity without inhibiting the RAS/RAF/MEK/ERK signaling pathway, while pemetrexed induced autophagy, which activated the AMPK/mTOR signaling pathway. Conclusion Taken together, these findings indicate that, in addition to apoptosis, pemetrexed-induced autophagy and cellular senescence, providing a promising direction for the development of KRAS-targeted therapy.
PARP Biomarker
|
KRAS (KRAS proto-oncogene GTPase) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
KRAS mutation • BAX expression
|
pemetrexed
5ms
When used in combination with AraC, S63845 significantly increases the therapeutic efficacy of AraC in CD157-positive but not in CD157-negative AML cells, overcoming their baseline difference in AraC sensitivity. Conclusion CD157 has an important functional role in the biology of AML and it could be a promising candidate for the prospective identification of patients that could benefit from therapies exploiting Mcl-1 inhibition.
IO biomarker
|
BCL2L1 (BCL2-like 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
MCL1 expression • BAX expression
|
S63845
5ms
When used in combination with AraC, S63845 significantly increases the therapeutic efficacy of AraC in CD157-positive but not in CD157-negative AML cells, overcoming their baseline difference in AraC sensitivity. Conclusion CD157 has an important functional role in the biology of AML and it could be a promising candidate for the prospective identification of patients that could benefit from therapies exploiting Mcl-1 inhibition.
IO biomarker
|
BCL2L1 (BCL2-like 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
MCL1 expression • BAX expression
|
S63845
5ms
When used in combination with AraC, S63845 significantly increases the therapeutic efficacy of AraC in CD157-positive but not in CD157-negative AML cells, overcoming their baseline difference in AraC sensitivity. Conclusion CD157 has an important functional role in the biology of AML and it could be a promising candidate for the prospective identification of patients that could benefit from therapies exploiting Mcl-1 inhibition.
IO biomarker
|
BCL2L1 (BCL2-like 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
MCL1 expression • BAX expression
|
S63845
5ms
When used in combination with AraC, S63845 significantly increases the therapeutic efficacy of AraC in CD157-positive but not in CD157-negative AML cells, overcoming their baseline difference in AraC sensitivity. Conclusion CD157 has an important functional role in the biology of AML and it could be a promising candidate for the prospective identification of patients that could benefit from therapies exploiting Mcl-1 inhibition.
IO biomarker
|
BCL2L1 (BCL2-like 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
MCL1 expression • BAX expression
|
S63845
5ms
Our findings suggest that C. chinensis extract is able to inhibit proliferation and induce apoptosis in PC3 and MCF7 cell lines. Therefore, C. chinensis extract exerts antitumor activity against cancer cells.
Preclinical • Journal • IO biomarker
|
PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
5ms
Our findings indicate that DLA, DL, and DP inhibit tumor growth in MCF-7 xenograft nude mice by regulating the homeostasis of gut microbiota, producing SCFAs, and then disturbing the expression of cancer-related proteins. The present study suggests three phytosterols as gut microbiota regulator for breast cancer prevention.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • MUC1 (Mucin 1) • CEACAM5 (CEA Cell Adhesion Molecule 5) • MUC16 (Mucin 16, Cell Surface Associated) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
BAX expression
5ms
Furthermore, oral administration of CR suppressed Hep3B tumor growth in xenograft mice without toxicity, alterations to body weight, or changes in hematological and biochemical profiles. Taken together, our findings suggest that CR has anti-tumor effects that result from ROS generation, and may be a potential pharmacological intervention for HCC.
Journal • PARP Biomarker • IO biomarker
|
BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
5ms
Subsequently, we manipulated miRNA-34a-5p expression through cell transfection and observed abnormal expression of β-catenin as well as the downstream targets of the Wnt/β-catenin pathway in neuroblastoma cells. With all these evidences, we determined that miRNA-34a-5p regulated Wnt/β-catenin pathway by targeting SOX4.In conclusion, our study demonstrates that miRNA-34a-5p can inhibit the over-activation of the Wnt/β-catenin signaling pathway via targeting SOX4 and further regulate proliferation, invasion of neuroblastoma cells.
Observational data • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MIR34A (MicroRNA 34a-5p) • MMP9 (Matrix metallopeptidase 9) • SOX4 (SRY-Box Transcription Factor 4)
|
BAX expression
5ms
In conclusion, khat induces significant cellular and molecular changes that could potentially cause a wide range of serious diseases and syndromes. Such an impact could have a heavy burden on the health care system in the countries where khat is consumed.
Journal
|
TP53 (Tumor protein P53) • IL6 (Interleukin 6) • CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2)
|
CDH1 expression • BAX expression • IL6 expression
5ms
The sensitivity of the downregulation of myeloid leukemia factor 1-interacting proteins (MLF1IP) to Tamoxifen (TAM) was tested by the Cell Counting Kit-8 (CCK-8)...(2) MLF1IP promotes AKT phosphorylation by inhibiting the PTEN expression, thus activating the PI3K/AKT signaling pathway and causing the secondary resistance of Luminal breast cancer. (3) MLF1IP can be used as a factor to predict the endocrine resistance of Luminal breast cancer.
Journal • IO biomarker
|
PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CASP3 (Caspase 3) • CASP7 (Caspase 7)
|
PTEN expression • BCL2 expression • BAX expression
|
tamoxifen
5ms
Erianin can inhibit the proliferation of TNBC cells and induce cell cycle arrest and apoptosis, which may ascribe to the abolish the activation of the PI3K/Akt pathway.
Journal • PARP Biomarker
|
CASP3 (Caspase 3) • CASP9 (Caspase 9) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
BAX expression
5ms
IL-32 can improve the radiosensitivity of ESCC cells by inhibiting the STAT3 pathway. Therefore, IL-32 can be used as a new therapeutic target to provide a new attempt for radiotherapy of ESCC.
Journal
|
BAX (BCL2-associated X protein) • IL32 (Interleukin 32)
|
BAX expression
5ms
Schistosomiasis may be involved in the development and progression of CRC through affecting Bcl-2 and Bax gene expression in the apoptosis signaling pathway.
Clinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
5ms
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
5ms
Furthermore, ESS treatment significantly induced anti-apoptotic effect indicated by elevation of both Bcl-2 and Bax expressions. Nutriceutics of ESS extract protects testis against ACR-induced testicular toxicity via normalizing testicular steroidogenesis, keeping Leydig cells, and improving oxidative stress status.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PCNA (Proliferating cell nuclear antigen)
|
BCL2 expression • BAX expression
5ms
Our study indicates that SphK1-SIP axis may potentiate neuroinflammatory responses and mediate brain damage through neuronal apoptosis, and DSCXQ could suppress the activity of SphK1-SIP axis to protect brain tissue in cerebral ischemia. In conclusion, this study facilitates our understanding of metabolic changes in ischemia stroke and the underlying mechanisms related to the clinical application of DSCXQ.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
BCL2 expression • BAX expression
5ms
EGCs can protect neurons from hyperglycemia-induced injury by activating the Akt/GSK-3β pathway.
Journal
|
CCND1 (Cyclin D1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • GSK3B (Glycogen Synthase Kinase 3 Beta)
|
CCND1 expression • BAX expression
5ms
The results indicated that LPE could protect H9c2 cells from oxidative stress through five active components. LPE has the potential to be developed into natural medicine or health food for the inhibition of cell oxidative damage.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • HMOX1 (Heme Oxygenase 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CAT (Catalase)
|
BCL2 expression • BAX expression • HMOX1 expression
5ms
Down-regulation of C1orf63 acts on the NF-κB signaling pathway to regulate the expression of p-IκBα, CyclinD1, and CDK4, so as to inhibit BCC proliferation, promote cell apoptosis, and block the cell cycle.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BAX (BCL2-associated X protein) • UBQLN4 (Ubiquilin 4)
|
CCND1 expression • BAX expression
5ms
Immunohistochemical staining showed that CRP expression was upregulated in TSCC tissues from cisplatin-resistant patients compared with that in cisplatin-sensitive TSCC samples...Taken together, our findings indicate that CRP promotes TSCC chemoresistance by inhibiting the activation of caspase-3/9 via the FcγRI/AKT/mTOR pathway. Thus, CRP could potentially be considered as a therapeutic target for reducing TSCC chemoresistance.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • CRP (C-reactive protein)
|
BCL2 expression • BAX expression
|
cisplatin
5ms
Also, the expression pattern of miR-21, miR-29a, and Bax/Bcl-2 ratio in KMBC/71 and MCF-7 mammospheres was different in response to GO-Cur and GQDs-Cur. Although KMBC/71 and MCF-7 tumor cells had similar clinical features and displayed similar responses to curcumin, more investigations are needed to clarify the detailed molecular mechanisms underlying observed differences in response to GO-Cur and GQDs-Cur.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MIR21 (MicroRNA 21) • BAX (BCL2-associated X protein) • MIR29A (MicroRNA 29a)
|
BCL2 expression • BAX expression
5ms
Silencing IGFBP4 had the opposite effects. BVP could inhibit the growth of NSCLC A549 cells by promoting apoptosis via ROS-mediated upregulation of IGFBP4.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression • BAX expression
5ms
Maternal treadmill running or treadmill running of offspring inhibited Bax expression and increased Bcl-2 expression in the hippocampus of adolescent and adult offspring rats born to maternal rats receiving stress during pregnancy. Mother's exercise during pregnancy or child's exercise after childbirth can improve the spatial learning ability deteriorated due to stress during pregnancy.
Preclinical • Journal • IO biomarker
|
NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
|
BCL2 expression • BAX expression
5ms
Resistance exercise improved short-term memory by inhibiting secretion of proinflammatory cytokines and apoptosis through inactivation of NF-κB. These effects of resistance exercise were similar to levodopa treatment.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta)
|
BCL2 expression • BAX expression
5ms
These findings indicate that pawpaw extracts are natural therapeutic agents that may be used for the prevention and treatment of gastric and cervical cancers, and encourage further studies on the anti-inflammatory potential of the pawpaw tree.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3)
|
BAX expression
5ms
Mechanistically, the combination treatment of BBR and DDP inhibited the expression of MMP-2/9, Bcl-2, CyclinD1, and CDK4, enhanced the expression of Bax and regulated the activity of the MAPK pathway. Collectively, our data suggest that the combination therapy of BBR and DDP markedly enhanced OS cell death.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
BCL2 expression • CCND1 expression • BAX expression
|
cisplatin
5ms
Taken together, this is the first study showing that BA suppresses the proliferation of human bladder cancer cells, which is due to induction of apoptosis, necrosis, and cell cycle arrest, and decrease of migration and invasion. Furthermore, BA-induced apoptosis is regulated by caspase-dependent and ROS-independent pathways, and these results provide the underlying anti-proliferative molecular mechanism of BA in human bladder cancer cells.
Preclinical • Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CCNA2 (Cyclin A2) • MMP9 (Matrix metallopeptidase 9) • CCNB1 (Cyclin B1) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
|
BCL2 expression • BAX expression
5ms
Debio-0932 decreased the migration of HUVEC cells as compared to the control group. These results indicate that Debio-0932 is a promising compound to treat triple-negative breast cancer and hormone receptor-positive breast cancer, and their metastases.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP9 (Caspase 9)
|
HR positive • BCL2 expression • BAX expression
|
CUDC-305
5ms
This research suggested that by interacting with miR-184, tripterine could restrain the progression of BC. This knowledge could be instrumental in developing highly effective treatment solutions for BC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • MIR184 (MicroRNA 184)
|
BCL2 expression • BAX expression • miR-184 expression
5ms
The inhibitory effect of Nek2 silencing on the cell viability was mainly realized by the inhibition of ERK/MAPK signaling. Nek2 plays an important role in the regulation of the progression of breast cancer in vitro probably through regulating the ERK/MAPK signaling.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • IGF1 (Insulin-like growth factor 1) • BAX (BCL2-associated X protein) • CCNB1 (Cyclin B1) • NEK2 (NIMA Related Kinase 2)
|
BCL2 expression • CCND1 expression • BAX expression • CDKN1B expression
5ms
miR-181a promotes the up-regulation of Col-1 and Col-3, and regulates the proliferation and apoptosis of HSFb by targeting PTEN, thereby enhancing the formation of hypertrophic scarring (HS). Therefore, miR-181a and PTEN may be potential therapeutic targets for the treatment of HS.
Journal • IO biomarker
|
PTEN (Phosphatase and tensin homolog) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
PTEN expression • BCL2 expression • BAX expression
5ms
CPI-455 inhibited Eca-109 cell proliferation via mitochondrial apoptosis by regulating the expression of related genes.
Preclinical • Journal
|
TP53 (Tumor protein P53) • CASP3 (Caspase 3) • KDM5C (Lysine Demethylase 5C) • CASP9 (Caspase 9)
|
TP53 expression • BAX expression
|
gemcitabine
5ms
In summary, we validated the high expression of circPLXNB2 and PLXNB2 in patients with AML. Elevated circPLXNB2 levels were associated with poor clinical outcomes in patients with AML. Importantly, circPLXNB2 accelerated tumour growth and progression, possibly by regulating PLXNB2 expression. Our study highlights the potential of circPLXNB2 as a new prognostic predictor and therapeutic target for AML in the future.
Clinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BAX (BCL2-associated X protein)
|
BCL2 expression • CCND1 expression • BAX expression
5ms
Huanglian decoction has a significant inhibitory effect on HCC cells. CCNB1 is a potential therapeutic target in HCC. Further analysis showed that Huanglian decoction can inhibit HCC cell growth by downregulating the expression of CCNB1 to activate the p53 signaling pathway.
Journal
|
BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
TP53 expression • BAX expression
5ms
ERK inhibition significantly attenuated the anticancer effect of 17BIPHE2. The present observations suggested that 17BIPHE2 can effectively inhibit cancer cells by regulating the ERK signaling pathway.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
BCL2 expression • BAX expression
5ms
NF-κB was upregulated in colon cancer cell lines, while inhibition of NF-κB reversed functions of lncRNA CASC2 and magnified roles of miR-19a. Our findings showed that lncRNA CASC2 inhibited cell viability in colon cancer cell lines and miR-19a reversed its functions through the NF-κB signalling pathway, suggesting that these could be factors in treating colon cancer in the future.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • RELA (RELA Proto-Oncogene)
|
BCL2 expression • BAX expression
5ms
The average overall survival of patients with MCL is 4-6 years and for the majority of patients who progress on targeted agents like ibrutinib, survival remains at a dismal 3-8 months. Both PDX models showed an extension of life with combination treatment (P<0.001) and delayed disease progression (P<0.05). Conclusion This preclinical data provides mechanistic rationale while demonstrating therapeutic synergy and lack of toxicity in this preclinical study and justifies further consideration of this combination strategy targeting PRMT5 and BCL2 in MCL in the clinical setting.
IO biomarker
|
BAX (BCL2-associated X protein) • FOXO1 (Forkhead box O1) • PRMT5 (Protein Arginine Methyltransferase 5) • BAK1 (BCL2 Antagonist/Killer 1)
|
BAX expression
|
Venclexta (venetoclax) • ibrutinib
5ms
Our in vivo xenograft model also revealed similar findings, such as downregulation of CDK-2 (p < 0.0001) and CDK-4 (p < 0.0142) and upregulation of Bax (p < 0.0001), cytochrome C (p < 0.0001), cleaved caspase 3 (p < 0.0001) and cleaved caspase 9 (p < 0.0001). In summary, our study revealed that DA is an effective treatment against B16F10 melanoma cells and xenograft mice model.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CDK2 (Cyclin-dependent kinase 2) • CASP9 (Caspase 9) • BECN1 (Beclin 1)
|
BCL2 expression • BAX expression
5ms
Gαi1 positively regulates the activation of the mTOR and Erk pathways. In conclusion, this study reveals Gαi1 promoted proliferation via activating the Akt-mTOR and Erk-MAPK signaling pathways in RCC, and Gαi1 may be a therapeutic and prognostic target for RCC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • BAX (BCL2-associated X protein) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
CCND1 expression • BAX expression • CCND1 expression + CDK4 expression
5ms
Overexpression of EGR1 or EGR2 promoted phosphatase and tension homolog (PTEN) or Bcl-2-associated X (BAX) expression, and EGR1 or EGR2 was able to directly bind to the promoter region of PTEN or BAX. In conclusion, we found that the altered expression of EGR1/2 affected the proliferation of PTC cells and regulated the expression of PTEN and BAX.
Journal • IO biomarker
|
PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • EGR1 (Early Growth Response 1)
|
PTEN expression • BAX expression
5ms
Ethanol-induced activation of NF-κB signaling was suppressed by astragaloside in vitro and in vivo, suggesting that astragaloside inhibited oxidative stress by suppressing the activation of NF-κB signaling, thus improving liver function and alleviating AFLD in rats. Our study elucidates the pharmacological mechanism of astragaloside and provides potential therapeutic strategies for AFLD.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
|
BCL2 expression • BAX expression
5ms
In conclusion, the findings of the present study suggested that the downregulation of USP46 expression levels may promote DDP resistance in OC, which may be regulated by PUM2. Therefore, targeting PUM2/USP46 may be an effective way to reverse DDP resistance in OC.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP9 (Caspase 9)
|
BCL2 expression • BAX expression
|
cisplatin
5ms
We found that silencing of MICAL1 could significantly reduce the levels of the nuclear factor erythroid 2-related factor 2 (Nrf2), increase the expression of pro-apoptotic factors (Bax and C-caspase 3), decrease the levels of anti-apoptotic factor (Bcl-2) and pro-autophagy factors ( Beclin1 and LC3B). Therefore, MICAL1 is a potential target gene for SCI clinical therapy.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • CASP3 (Caspase 3) • BECN1 (Beclin 1)
|
BAX expression